1
|
Katsuya Y, Yoshida T, Takashima A, Yonemori K, Ohba A, Yazaki S, Yagishita S, Nakahama H, Kobayashi O, Yanagida M, Irino Y, Hamada A, Yamamoto N. Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. Int J Clin Oncol 2024; 29:386-397. [PMID: 38381163 PMCID: PMC10963526 DOI: 10.1007/s10147-024-02470-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2023] [Accepted: 01/05/2024] [Indexed: 02/22/2024]
Abstract
BACKGROUND Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines. METHODS This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1-3 and 4-6 months after the second vaccination. The primary endpoint was the seroconversion rate measured 1-3 months after the second vaccine. RESULTS In total, 590 patients and 183 healthy hospital staff were analyzed. At 1-3 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/mL) in 96.1% (567/590) of the patients with cancer and 100% (183/183) of the healthy controls (p = 0.0024). At 4-6 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/ml for S-IgG) in 93.1% (461/495) of the patients with cancer and 100% (170/170) of the healthy controls (p < 0.0001). Old age, being male, and low lymphocyte count were related to low SARS-CoV-2 S-IgG levels 1-3 months after the second vaccination among patients, while body mass index, smoking history, and serum albumin level were not. Patients undergoing platinum combination therapy and alkylating agent among cytotoxic drugs, and PARP inhibitor, mTOR inhibitor, and BCR-ABL inhibitor exhibited a low S-IgG antibody concentration compared to the no treatment group. CONCLUSIONS COVID-19 vaccine immunogenicity was reduced among patients with cancer, especially under several treatment regimens.
Collapse
Affiliation(s)
- Yuki Katsuya
- Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan.
| | - Tatsuya Yoshida
- Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Atsuo Takashima
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Kan Yonemori
- Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Akihiro Ohba
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Shu Yazaki
- Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Shigehiro Yagishita
- Division of Molecular Pharmacology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Hiroko Nakahama
- Department of Nursing, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Osamu Kobayashi
- Department of Infectious Diseases, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Masatoshi Yanagida
- Applied Diagnostic Research Group, Central Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe, 651-2271, Japan
| | - Yasuhiro Irino
- Applied Diagnostic Research Group, Central Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Nishi-ku, Kobe, 651-2271, Japan
| | - Akinobu Hamada
- Division of Molecular Pharmacology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| | - Noboru Yamamoto
- Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan
| |
Collapse
|
2
|
Fukuda A, Yoshida T, Yagishita S, Shiotsuka M, Kobayashi O, Iwata S, Umeguchi H, Yanagida M, Irino Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Yamamoto N, Ohe Y. Real-world Data on the Incidence of Coronavirus Disease (COVID-19) in Patients With Advanced Thoracic Cancer During the Early Phase of the Pandemic in Japan. Anticancer Res 2023; 43:919-926. [PMID: 36697081 DOI: 10.21873/anticanres.16235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Revised: 12/29/2022] [Accepted: 01/04/2023] [Indexed: 01/26/2023]
Abstract
BACKGROUND/AIM The severity and associated mortality of coronavirus disease 2019 (COVID-19) are higher in patients with thoracic cancer than in healthy populations and those with other cancer types. Here, we investigated real-world data on the incidence of COVID-19 and false-negative cases using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) real-time reverse-transcription polymerase chain reaction (rRT-PCR) testing in patients with thoracic cancer. PATIENTS AND METHODS We retrospectively reviewed patients with advanced thoracic cancer at the National Cancer Center Hospital between March 2020-May 2021. Blood samples were collected and evaluated for IgM and IgG antibodies specific for nucleocapsid (N) and spike (S) protein SARS-CoV-2 before and after rRT-PCR testing. False-negative cases were assessed based on anti-SARS-CoV-2 antibody levels before and after rRT-PCR testing. RESULTS A total of 2,107 patients with thoracic cancer were identified between March 2020 and May 2021, 7 (0.3%) of whom developed COVID-19. Among the 218 patients who underwent at least one rRT-PCR test because of suspected COVID-19 symptoms or as a screening test at our institute, the most common diagnosis was non-COVID-19 pneumonia (34.4%), followed by tumor fever (30.7%). Furthermore, of the 218 patients, 120 paired serum samples before and after rRT-PCR testing were available. Seroconversion was identified in all three patients with positive SARS-CoV-2 rRT-PCR results but was only observed in 1 out of the 117 patients who tested negative; the rate of false-negative cases was low (0.9%). CONCLUSION COVID-19 incidence among patients with advanced thoracic cancer was low during the early phase of the pandemic in Japan.
Collapse
Affiliation(s)
- Akito Fukuda
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Tatsuya Yoshida
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan;
| | - Shigehiro Yagishita
- Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan
| | - Mika Shiotsuka
- Department of Infectious Diseases, National Cancer Center Hospital, Tokyo, Japan
| | - Osamu Kobayashi
- Department of Infectious Diseases, National Cancer Center Hospital, Tokyo, Japan
| | - Satoshi Iwata
- Department of Infectious Diseases, National Cancer Center Hospital, Tokyo, Japan
| | - Hitomi Umeguchi
- Department of Pulmonary Disease, Saga Medical Center, Saga, Japan
| | | | - Yasuhiro Irino
- Central Research Laboratories, Sysmex Corporation, Hyogo, Japan
| | - Ken Masuda
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Yuki Shinno
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Yusuke Okuma
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Yasushi Goto
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Hidehito Horinouchi
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Akinobu Hamada
- Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan
| | - Noboru Yamamoto
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Yuichiro Ohe
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
3
|
Sakaeda K, Kurose K, Fukuda M, Sugasaki N, Kinoshita A, Kitazaki T, Fukuda M, Masuda T, Hattori N, Atarashi Y, Sakai Y, Irino Y, Yamaki M, Sato T, Mukae H, Oga T, Oka M. Abstract A61: Development of automated immunoassay to detect serum biomarkers predicting response to immune checkpoint inhibitors in NSCLC. Cancer Immunol Res 2022. [DOI: 10.1158/2326-6074.tumimm22-a61] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
Abstract
Introduction: Immunotherapy with immune checkpoint inhibitors (ICI) is the standard of care for advanced non-small-cell lung cancer (NSCLC) without driver gene alterations. However, survival benefits with ICI are limited to a small subset of NSCLC patients, and particularly ICI combinations with cytotoxic agents produce serious physical and large financial toxicities. Tumor PD-L1 expression levels/proportion score (TPS) are universally used as predictive biomarkers in ICI monotherapy response and outcomes. However, PD-L1/TPS assays are imperfect because of low analytical validity and reproducibility due to the visual-scoring system by pathologists. Therefore, additional biomarkers are urgently needed to predict ICI therapy response and outcomes. Recently, we reported that serum antibodies (Abs) against NY-ESO-1 and XAGE1 cancer-testis antigens were probably useful biomarkers in the prediction of clinical benefits with anti-PD-1 monotherapy for NSCLC (J Thorac Oncol, 2019). Additionally, we developed a fully automated immunoassay system (HISCLTM) to measure the Abs easily and rapidly (Sakai Y, et al. Clin Chim Acta 2021). In this study, we retrospectively examined whether the Abs measured by HISCLTM predict the clinical benefits with ICI monotherapy for NSCLC.Patients and Methods: Sera were obtained from controls of non-malignant lung diseases (n=75) and healthy subjects (n=100), and advanced NSCLC patients (n=263) to to determine a cutoff value in HISCLTM. In NSCLC patients analyzed here (n=78), sera were obtained before anti-PD-1 monotherapy with nivolumab in second-line or later settings. The serum NY-ESO-1/XAGE1 Abs were measured by HISCLTM, and we examined the relationships between the Abs levels, objective response rate (ORR), progression free survival (PFS), and overall survival (OS) after nivolumab monotherapy.Results: NY-ESO-1/XAGE1 Abs levels in NSCLC patients (n=263) were significantly higher than those in the controls (n=175). A cutoff value was determined as the Abs level of 10 SU/mL, calculated from the Abs values in the controls. The Abs (≥ 10 SU/mL) were detected in 21/78 (27%) of the NSCLC patients treated with nivolumab, and one patient had both NY-ESO-1 and XAGE1 Ab. An ORR was 62%, 16%, and 29% in the Abs-positives, the Abs-negatives, and overall, respectively. The Abs levels in responders were significantly higher than those in non-responders. The NSCLC patients with high-Abs values (≥ 10 SU/mL) had significantly better survivals with nivolumab monotherapy than those with low-Abs (PFS, HR 0.51, 95%CI 0.31-0.83, p < 0.01; OS, HR 0.51, 95%CI 0.31-0.84, p < 0.01). Interestingly, a few NSCLC patients with both high-Abs and driver genes responded well to nivolumab.Conclusions: Serum NY-ESO-1/XAGE1 Abs measured by HISCLTM are potential biomarkers that predict clinical benefits with anti-PD-1 monotherapy for NSCLC, even including driver genes. These findings warrant further biomarker studies using NY-ESO-1/XAGE1 Abs in clinical trial and practice of NSCLC immunotherapy.
Citation Format: Kanako Sakaeda, Koji Kurose, Minoru Fukuda, Nanae Sugasaki, Akitoshi Kinoshita, Takashi Kitazaki, Masaaki Fukuda, Takeshi Masuda, Noboru Hattori, Yusuke Atarashi, Yumiko Sakai, Yasuhiro Irino, Mami Yamaki, Toshiyuki Sato, Hiroshi Mukae, Toru Oga, Mikio Oka. Development of automated immunoassay to detect serum biomarkers predicting response to immune checkpoint inhibitors in NSCLC [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl):Abstract nr A61.
Collapse
Affiliation(s)
| | - Koji Kurose
- 2Department of Respiratory Medicine, Kawasaki Medical School, Kurashiki, Japan,
| | - Minoru Fukuda
- 3Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan,
| | - Nanae Sugasaki
- 4Nagasaki Prefectural Shimabara Hospital, Nagasaki, Japan,
| | | | - Takashi Kitazaki
- 5The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan,
| | - Masaaki Fukuda
- 5The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan,
| | - Takeshi Masuda
- 6Department of Respiratory Medicine, Hiroshima University Hospital, Nagasaki, Japan,
| | - Noboru Hattori
- 7Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan,
| | | | | | | | | | | | - Hiroshi Mukae
- 3Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan,
| | - Toru Oga
- 9Department of Respiratory Medicine, Kawasaki Medical School, Nagasaki, Japan,
| | - Mikio Oka
- 10Immuno-Oncology, Kawasaki Medical School, Kurashiki, Japan
| |
Collapse
|
4
|
Yamashita K, Miura M, Watanabe S, Ishiki K, Arimatsu Y, Kawahira J, Kubo T, Sasaki K, Arai T, Hagino K, Irino Y, Nagai K, Verbel D, Koyama A, Dhadda S, Niiro H, Iwanaga S, Sato T, Yoshida T, Iwata A. Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy. Alzheimers Res Ther 2022; 14:86. [PMID: 35739591 PMCID: PMC9219197 DOI: 10.1186/s13195-022-01029-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 06/15/2022] [Indexed: 11/10/2022]
Abstract
Abstract
Background
Clinicians, researchers, and patients alike would greatly benefit from more accessible and inexpensive biomarkers for neural β-amyloid (Aβ). We aimed to assess the performance of fully automated plasma Aβ immunoassays, which correlate significantly with immunoprecipitation mass spectrometry assays, in predicting brain Aβ status as determined by visual read assessment of amyloid positron emission tomography (PET).
Methods
The plasma Aβ42/Aβ40 ratio was measured using a fully automated immunoassay platform (HISCL series) in two clinical studies (discovery and validation studies). The discovery and validation sample sets were retrospectively and randomly selected from participants with early Alzheimer’s disease (AD) identified during screening for the elenbecestat Phase 3 program.
Results
We included 197 participants in the discovery study (mean [SD] age 71.1 [8.5] years; 112 females) and 200 in the validation study (age 70.8 [7.9] years; 99 females). The plasma Aβ42/Aβ40 ratio predicted amyloid PET visual read status with areas under the receiver operating characteristic curves of 0.941 (95% confidence interval [CI] 0.910–0.973) and 0.868 (95% CI 0.816–0.920) in the discovery and validation studies, respectively. In the discovery study, a cutoff value of 0.102 was determined based on maximizing the Youden Index, and the sensitivity and specificity were calculated to be 96.0% (95% CI 90.1–98.9%) and 83.5% (95% CI 74.6–90.3%), respectively. Using the same cutoff value, the sensitivity and specificity in the validation study were calculated to be 88.0% (95% CI 80.0–93.6%) and 72.0% (95% CI 62.1–80.5%), respectively.
Conclusions
The plasma Aβ42/Aβ40 ratio measured using the HISCL series achieved high accuracy in predicting amyloid PET status. Since our blood-based immunoassay system is less invasive and more accessible than amyloid PET and cerebrospinal fluid testing, it may contribute to the diagnosis of AD in routine clinical practice.
Collapse
|
5
|
Yamashita K, Miura M, Watanabe S, Ishiki K, Arimatsu Y, Kawahira J, Kubo T, Sasaki K, Arai T, Hagino K, Irino Y, Nagai K, Verbel D, Koyama A, Dhadda S, Niiro H, Iwanaga S, Sato T, Yoshida T, Iwata A. Highly specific plasma β‐amyloid assays on the fully automated platform predict brain β‐amyloid pathology determined by a Centiloid threshold of amyloid PET. Alzheimers Dement 2022. [DOI: 10.1002/alz.068727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | | | | | | | - Toshiko Kubo
- Sysmex R&D Center Americas, Inc. Mundelein IL USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. Adv Clin Chem 2022; 112:155-204. [PMID: 36642483 DOI: 10.1016/bs.acc.2022.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Immune checkpoint inhibitors (ICI) are key drugs in systemic therapy for advanced non-small-cell lung cancer (NSCLC) and have recently been incorporated into neoadjuvant and adjuvant settings for surgical resection. Currently, ICI combinations with cytotoxic agents are frequently used in clinical practice, although several ICI clinical trials have failed to produce long-term clinical benefits. Unfortunately, clinical benefit is moderate and limited considering physical and financial burden. Therefore, selecting appropriate patients and regimens for ICI therapy is important, and biomarkers are necessary for their selection. Tumor PD-L1 expression is universally used as a biomarker; however, PD-L1 assays show low analytical validity and reproducibility due to the visual-scoring system by pathologists. Recent tumor immunology studies explore that neoantigens derived from somatic mutations and the collaboration between T and B cells efficiently elicit antitumor responses. This suggests that high tumor mutational burden and T-cell infiltration are predictive biomarkers. However, B cells producing antibody (Ab) remain poorly understood and analyzed as biomarkers. We found that NY-ESO-1 and XAGE1 of cancer-testis antigen frequently elicit spontaneous humoral and cellular immune responses in NSCLC. Serum Ab against these antigens were detected in approximately 25% of NSCLC patients and predicted ICI monotherapy responses. In addition, the Ab levels were decreased with tumor shrinkage after ICI therapy. Thus, NY-ESO-1 and XAGE1 Ab are potentially biomarkers predicting and monitoring response to ICI therapy. For clinical applications, a fully-automated assay system measuring the Ab was developed. Here, we review current ICI therapy, tumor immunology, and biomarkers in NSCLC, and discuss the applicability of the serum biomarkers NY-ESO-1 and XAGE1 Ab.
Collapse
Affiliation(s)
- Koji Kurose
- Department of Respiratory Medicine, Kawasaki Medical School, Okayama, Japan
| | - Kanako Sakaeda
- Central Research Laboratories, Sysmex Corporation, Hyogo, Japan
| | - Minoru Fukuda
- Cancer Treatment Center, Nagasaki Prefecture Shimabara Hospital, Nagasaki, Japan
| | - Yumiko Sakai
- Central Research Laboratories, Sysmex Corporation, Hyogo, Japan
| | - Hiroyuki Yamaguchi
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Shinnosuke Takemoto
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | | | - Takeshi Masuda
- Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan
| | - Katsumi Nakatomi
- Department of Respiratory Medicine, NHO Ureshino Medical Center, Saga, Japan
| | - Shigeo Kawase
- Department of Respiratory Medicine, Kure Kyosai Hospital, Hiroshima, Japan
| | - Ryo Tanaka
- Department of Dermatology, Kawasaki Medical School, Okayama, Japan
| | - Takayuki Suetsugu
- Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Keiko Mizuno
- Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | | | - Yusuke Atarashi
- Central Research Laboratories, Sysmex Corporation, Hyogo, Japan
| | - Yasuhiro Irino
- Central Research Laboratories, Sysmex Corporation, Hyogo, Japan
| | - Toshiyuki Sato
- Central Research Laboratories, Sysmex Corporation, Hyogo, Japan
| | - Hiromasa Inoue
- Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
| | - Noboru Hattori
- Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Science, Hiroshima University, Hiroshima, Japan
| | - Eiichiro Kanda
- Department of Medical Science, Kawasaki Medical School, Okayama, Japan
| | - Masao Nakata
- General Thoracic Surgery, Kawasaki Medical School, Okayama, Japan
| | - Hiroshi Mukae
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
| | - Toru Oga
- Department of Respiratory Medicine, Kawasaki Medical School, Okayama, Japan
| | - Mikio Oka
- Department of Immuno-Oncology, Kawasaki Medical School, Okayama, Japan.
| |
Collapse
|
7
|
Yoshikawa S, Nagao M, Toh R, Shinohara M, Iino T, Irino Y, Nishimori M, Tanaka H, Satomi-Kobayashi S, Ishida T, Hirata KI. Inhibition of glutaminase 1-mediated glutaminolysis improves pathological cardiac remodeling. Am J Physiol Heart Circ Physiol 2022; 322:H749-H761. [PMID: 35275762 DOI: 10.1152/ajpheart.00692.2021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Alterations in cardiac metabolism are strongly associated with the pathogenesis of heart failure (HF). We recently reported that glutamine-dependent anaplerosis, termed glutaminolysis, was activated by H2O2 stimulation in rat cardiomyocytes, which seemed to be an adaptive response by which cardiomyocytes survive acute stress. However, the molecular mechanisms and fundamental roles of glutaminolysis in the pathophysiology of the failing heart are still unknown. Here, we treated wild-type mice (C57BL/6J) and rat neonatal cardiomyocytes (RNCMs) and fibroblasts (RNCFs) with angiotensin II (Ang II) to induce pathological cardiac remodeling. Glutaminase 1 (GLS1), a rate-limiting glutaminolysis enzyme, was significantly increased in Ang II-induced mouse hearts, RNCMs and RNCFs. Unexpectedly, a GLS1 inhibitor attenuated Ang II-induced left ventricular hypertrophy and fibrosis in the mice, and gene knockdown and pharmacological perturbation of GLS1 suppressed hypertrophy and the proliferation of RNCMs and RNCFs, respectively. Using mass spectrometry (MS)-based stable isotope tracing with 13C-labeled glutamine, we observed glutamine metabolic flux in Ang II-treated RNCMs and RNCFs. The incorporation of 13C atoms into tricarboxylic acid (TCA) cycle intermediates and their derivatives was markedly enhanced in both cell types, indicating the activation of glutaminolysis in hypertrophied heart. Notably, GLS1 inhibition reduced the production of glutamine-derived aspartate and citrate, which are required for the biosynthesis of nucleic acids and lipids, possibly contributing to the suppression of cardiac hypertrophy and fibrosis. The findings of the present study reveal that GLS1-mediated upregulation of glutaminolysis leads to maladaptive cardiac remodeling. Inhibition of this anaplerotic pathway could be a novel therapeutic approach for HF.
Collapse
Affiliation(s)
- Sachiko Yoshikawa
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Kobe, Hyogo, Japan
| | - Manabu Nagao
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Kobe, Hyogo, Japan
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Kobe, Hyogo, Japan
| | - Masakazu Shinohara
- Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan; The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuya Iino
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Kobe, Hyogo, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Makoto Nishimori
- Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Hidekazu Tanaka
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Seimi Satomi-Kobayashi
- Division of Cardiovascular Medicine, Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Kobe, Hyogo, Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Kobe, Hyogo, Japan
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, kobe, Japan
| |
Collapse
|
8
|
Watanabe S, Ishiki K, Yamashita K, Lukaszewska T, Miura M, Irino Y, Iwanaga S, Yoshida T. Characterization of AD pathology based on plasma biomarkers measured by a fully automated immunoassay system (HISCL
TM
series). Alzheimers Dement 2021. [DOI: 10.1002/alz.057571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
9
|
Matsuo K, Hosoda K, Tanaka J, Yamamoto Y, Imahori T, Nakai T, Irino Y, Shinohara M, Sasayama T, Kohmura E. Geranylgeranylacetone attenuates cerebral ischemia-reperfusion injury in rats through the augmentation of HSP 27 phosphorylation: a preliminary study. BMC Neurosci 2021; 22:9. [PMID: 33557752 PMCID: PMC7869466 DOI: 10.1186/s12868-021-00614-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 01/21/2021] [Indexed: 11/29/2022] Open
Abstract
Background We previously reported that heat shock protein 27 (HSP27) phosphorylation plays an important role in the activation of glucose-6-phosphate dehydrogenase (G6PD), resulting in the upregulation of the pentose phosphate pathway and antioxidant effects against cerebral ischemia–reperfusion injury. The present study investigated the effect of geranylgeranylacetone, an inducer of HSP27, on ischemia–reperfusion injury in male rats as a preliminary study to see if further research of the effects of geranylgeranylacetone on the ischemic stroke was warranted. Methods In all experiments, male Wistar rats were used. First, we conducted pathway activity profiling based on a gas chromatography–mass spectrometry to identify ischemia–reperfusion-related metabolic pathways. Next, we investigated the effects of geranylgeranylacetone on the pentose phosphate pathway and ischemia–reperfusion injury by real-time polymerase chain reaction (RT-PCR), immunoblotting, and G6PD activity, protein carbonylation and infarct volume analysis. Geranylgeranylacetone or vehicle was injected intracerebroventricularly 3 h prior to middle cerebral artery occlusion or sham operation. Results Pathway activity profiling demonstrated that changes in the metabolic state depended on reperfusion time and that the pentose phosphate pathway and taurine-hypotaurine metabolism pathway were the most strongly related to reperfusion among 137 metabolic pathways. RT-PCR demonstrated that geranylgeranylacetone did not significantly affect the increase in HSP27 transcript levels after ischemia–reperfusion. Immunoblotting showed that geranylgeranylacetone did not significantly affect the elevation of HSP27 protein levels. However, geranylgeranylacetone significantly increase the elevation of phosphorylation of HSP27 after ischemia–reperfusion. In addition, geranylgeranylacetone significantly affected the increase in G6PD activity, and reduced the increase in protein carbonylation after ischemia–reperfusion. Accordingly, geranylgeranylacetone significantly reduced the infarct size (median 31.3% vs 19.9%, p = 0.0013). Conclusions As a preliminary study, these findings suggest that geranylgeranylacetone may be a promising agent for the treatment of ischemic stroke and would be worthy of further study. Further studies are required to clearly delineate the mechanism of geranylgeranylacetone-induced HSP27 phosphorylation in antioxidant effects, which may guide the development of new approaches for minimizing the impact of cerebral ischemia–reperfusion injury.
Collapse
Affiliation(s)
- Kazuya Matsuo
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kohkichi Hosoda
- Department of Neurosurgery, Kobe City Nishi-Kobe Medical Center, 5-7-1, Kojidai, Nishi-ku, Kobe, Hyogo, 651-2273, Japan.
| | - Jun Tanaka
- Department of Neurosurgery, Konan Hospital, Kobe, Japan
| | - Yusuke Yamamoto
- Department of Neurosurgery, Toyooka Hospital, Toyooka, Japan
| | - Taichiro Imahori
- Department of Neurosurgery, Hyogo Brain and Heart Center at Himeji, Himeji, Japan
| | - Tomoaki Nakai
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masakazu Shinohara
- Division of Medical Education, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takashi Sasayama
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Eiji Kohmura
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
10
|
Iino T, Watanabe S, Yamashita K, Tamada E, Hasegawa T, Irino Y, Iwanaga S, Harada A, Noda K, Suto K, Yoshida T. Quantification of Amyloid-β in Plasma by Simple and Highly Sensitive Immunoaffinity Enrichment and LC-MS/MS Assay. J Appl Lab Med 2021; 6:834-845. [DOI: 10.1093/jalm/jfaa225] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 10/23/2020] [Indexed: 12/20/2022]
Abstract
Abstract
Background
Numerous immunoassays have been developed to quantify amyloid β1-40 (Aβ40) and amyloid β1-42 (Aβ42). Nevertheless, given the low concentration of Aβ and the high levels of interfering factors in plasma, quantification of plasma Aβ is still challenging. To overcome the problems related to the specificity of Aβ immunoassays, this study aimed to develop an immunoaffinity enrichment and LC-MS/MS (IA-MS) assay.
Methods
We developed an IA-MS assay using antibody-labeled magnetic beads for purification and LC-MS/MS for Aβ quantification. To avoid the loss of Aβ due to aggregation in acidic buffer, we used alkaline elution buffer for immunoaffinity enrichment. The concentrations of the Aβs in plasma samples were measured, and the correlation between the plasma and cerebrospinal fluid (CSF) Aβ42/Aβ40 ratio was also evaluated.
Results
The intensities of the Aβ mass peaks were significantly higher with the alkaline elution buffer than with the acidic elution buffer (Aβ40: 3.6-fold, Aβ42: 5.4-fold). This assay exhibited high reproducibility (intra-assay and inter-assay precision, %CV <15), and the working ranges of Aβ40 and Aβ42 were determined to be 21.7 to 692.8 pg/mL and 5.6 to 180.6 pg/mL, respectively. The concentrations of Aβ40 and Aβ42 in plasma were measured by IA-MS, and the plasma Aβ42/Aβ40 ratio was correlated with the CSF Aβ42/Aβ40 ratio (rs = 0.439, P < 0.01).
Conclusions
The IA-MS assay has sufficient analytic performance for measuring endogenous Aβ40 and Aβ42 in plasma. This assay can lead to new lines of clinical discovery related to amyloid pathology.
Collapse
Affiliation(s)
- Takuya Iino
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | | | | | - Eiya Tamada
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | | | - Yasuhiro Irino
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Shigeki Iwanaga
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Amane Harada
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Kenta Noda
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Kouzou Suto
- Bio-Diagnostic Reagent Technology Center, Sysmex Corporation, Kobe, Japan
| | | |
Collapse
|
11
|
Tanaka K, Sasayama T, Nagashima H, Irino Y, Takahashi M, Izumi Y, Uno T, Satoh N, Kitta A, Kyotani K, Fujita Y, Hashiguchi M, Nakai T, Kohta M, Uozumi Y, Shinohara M, Hosoda K, Bamba T, Kohmura E. Glioma cells require one-carbon metabolism to survive glutamine starvation. Acta Neuropathol Commun 2021; 9:16. [PMID: 33468252 PMCID: PMC7814586 DOI: 10.1186/s40478-020-01114-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Accepted: 12/28/2020] [Indexed: 02/07/2023] Open
Abstract
Cancer cells optimize nutrient utilization to supply energetic and biosynthetic pathways. This metabolic process also includes redox maintenance and epigenetic regulation through nucleic acid and protein methylation, which enhance tumorigenicity and clinical resistance. However, less is known about how cancer cells exhibit metabolic flexibility to sustain cell growth and survival from nutrient starvation. Here, we find that serine and glycine levels were higher in low-nutrient regions of tumors in glioblastoma multiforme (GBM) patients than they were in other regions. Metabolic and functional studies in GBM cells demonstrated that serine availability and one-carbon metabolism support glioma cell survival following glutamine deprivation. Serine synthesis was mediated through autophagy rather than glycolysis. Gene expression analysis identified upregulation of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) to regulate one-carbon metabolism. In clinical samples, MTHFD2 expression was highest in the nutrient-poor areas around “pseudopalisading necrosis.” Genetic suppression of MTHFD2 and autophagy inhibition caused tumor cell death and growth inhibition of glioma cells upon glutamine deprivation. These results highlight a critical role for serine-dependent one-carbon metabolism in surviving glutamine starvation and suggest new therapeutic targets for glioma cells adapting to a low-nutrient microenvironment.
Collapse
|
12
|
Maeyama M, Tanaka K, Nishihara M, Irino Y, Shinohara M, Nagashima H, Tanaka H, Nakamizo S, Hashiguchi M, Fujita Y, Kohta M, Kohmura E, Sasayama T. Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model. Sci Rep 2021; 11:79. [PMID: 33420169 PMCID: PMC7794443 DOI: 10.1038/s41598-020-79465-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Accepted: 11/26/2020] [Indexed: 02/07/2023] Open
Abstract
The ketogenic diet (KD) is a high fat and low carbohydrate diet that produces ketone bodies through imitation of starvation. The combination of KD and Bevacizumab (Bev), a VEGF inhibitor, is considered to further reduce the supply of glucose to the tumor. The metabolite changes in U87 glioblastoma mouse models treated with KD and/or Bev were examined using gas chromatography-mass spectrometry. The combination therapy of KD and Bev showed a decrease in the rate of tumor growth and an increase in the survival time of mice, although KD alone did not have survival benefit. In the metabolome analysis, the pattern of changes for most amino acids are similar between tumor and brain tissues, however, some amino acids such as aspartic acid and glutamic acid were different between tumors and brain tissues. The KD enhanced the anti-tumor efficacy of Bev in a glioblastoma intracranial implantation mouse model, based on lowest levels of microvascular density (CD31) and cellular proliferation markers (Ki-67 and CCND1) in KD + Bev tumors compared to the other groups. These results suggested that KD combined with Bev may be a useful treatment strategy for patients with GBM.
Collapse
Affiliation(s)
- Masahiro Maeyama
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Kazuhiro Tanaka
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
| | | | - Yasuhiro Irino
- Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masakazu Shinohara
- Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Kobe, Japan.,Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Hiroaki Nagashima
- Department of Neurosurgery, Massachusetts General Hospital Research Institute, Boston, MA, USA
| | - Hirotomo Tanaka
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Satoshi Nakamizo
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Mitsuru Hashiguchi
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Yuichi Fujita
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Masaaki Kohta
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Eiji Kohmura
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| | - Takashi Sasayama
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
| |
Collapse
|
13
|
Watanabe K, Nagao M, Toh R, Irino Y, Shinohara M, Iino T, Yoshikawa S, Tanaka H, Satomi-Kobayashi S, Ishida T, Hirata KI. Critical role of glutamine metabolism in cardiomyocytes under oxidative stress. Biochem Biophys Res Commun 2020; 534:687-693. [PMID: 33213841 DOI: 10.1016/j.bbrc.2020.11.018] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 11/05/2020] [Indexed: 01/04/2023]
Abstract
BACKGROUND Metabolic remodeling in cardiomyocytes is deeply associated with the pathogenesis of heart failure (HF). Glutaminolysis is an anaplerotic pathway that incorporates α-ketoglutarate (αKG) derived from glutamine into the tricarboxylic acid (TCA) cycle. It is well known that cancer cells depend on glutamine for their increased energy demand and proliferation; however, the physiological roles of glutamine metabolism in failing hearts remain unclear. OBJECTIVE To investigate the regulatory mechanisms and biological effects of glutamine metabolism in oxidative stress-induced failing myocardium. METHODS AND RESULTS The intracellular levels of glutamine, glutamate, and αKG were significantly decreased by H2O2 stimulation in rat neonatal cardiomyocytes (RNCMs). To better understand the metabolic flux in failing myocardium, we performed a stable isotope tracing study and found that glutaminolysis was upregulated in RNCMs under oxidative stress. Consistent with this, the enzymatic activity of glutaminase (Gls), which converts glutamine to glutamate, was augmented in RNCMs treated with H2O2. These findings suggest that glutamine anaplerosis is enhanced in cardiomyocytes under oxidative stress to compensate for the reduction of αKG. Furthermore, the inhibition of Gls reduced cardiac cell viability, ATP production, and glutathione (GSH) synthesis in RNCMs with H2O2 stimulation. Finally, we evaluated the effects of αKG on failing myocardium and observed that dimethyl α-ketoglutarate (DMKG) suppressed oxidative stress-induced cell death likely due to the enhancement of intracellular ATP and GSH levels. CONCLUSION Our study demonstrates that under oxidative stress, glutaminolysis is upregulated to compensate for the loss of αKG and its replenishment into the TCA cycle, thereby exerting cardioprotective effects by maintaining ATP and GSH levels. Modulation of glutamine metabolism in failing hearts might provide a new therapeutic strategy for HF.
Collapse
Affiliation(s)
- Koichi Watanabe
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Manabu Nagao
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masakazu Shinohara
- Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan; The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takuya Iino
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Sachiko Yoshikawa
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Hidekazu Tanaka
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Seimi Satomi-Kobayashi
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
14
|
Fujimoto D, Otake H, Kawamori H, Toba T, Nagao M, Sugizaki Y, Nagasawa A, Takeshige R, Harada A, Murakami K, Iino T, Irino Y, Toh R, Hirata K. Cholesterol uptake capacity: a new measure of HDL functionality as a predictor of subsequent revascularization in patients undergoing percutaneous coronary intervention. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Recent studies have demonstrated the importance of high-density lipoprotein (HDL) functionality in the development of de novo coronary artery disease by using the cholesterol-efflux capacity, a measure of the ability of HDL to promote cholesterol removal from lipid-laden macrophages. Recently, we developed a rapid cell-free assay system to directly evaluate the capacity of HDL to accept additional cholesterol; the measurement of the cholesterol-uptake capacity (CUC) enables HDL functionality to be readily evaluated in our daily practice. However, prognostic implication of CUC measurement at the timing of percutaneous coronary intervention (PCI) remains unclear.
Purpose
We aimed to evaluate the association between baseline CUC and revascularization during follow-up in the patients who underwent PCI.
Methods
We retrospectively reviewed the patients who underwent PCI with follow-up coronary angiography (CAG) or ischemic-driven revascularization. The patients who had the frozen blood samples of which CUC were measurable at the index PCI and follow-up CAG or revascularization were enrolled. We excluded the patients under hemodialysis.
Results
Among a total of 703 consecutive patients who underwent PCI between Dec 2014 and Mar 2019, we finally enrolled 74 patients who underwent ischemic-driven revascularization (revascularization group) and 183 patients who underwent follow-up CAG without revascularization (non-revascularization group).There were no significant difference in baseline traditional cardiovascular risk factors between the groups. However, the presence of diabetes was significantly more frequent in the revascularization group (63.5% vs 41.0%; P=0.001) than in the non-revascularization group. CUC at the index PCI was significantly lower in the revascularization group than in the non-revascularization group (87.0±19.5 vs 93.9±19.2; P=0.004). Multivariate logistic regression analysis revealed that impaired HDL functionality assessed by decreased CUC level at the index PCI (odds ratio; 0.984, 95% confidence interval; 0.969–1.000) was independently associated with subsequent revascularization after PCI. Indeed, there was a graded inverse association between increasing tertiles of CUC levels and the incidence of revascularization during a median follow-up of 881 days (Figure). Especially in the subgroup analysis of non-diabetic patients, decreased CUC level at the index PCI was independently associated with subsequent revascularization (odds ratio; 0.947, 95% confidence interval; 0.915–0.981), while not in diabetic population.
Conclusion
Serum CUC level at the index procedure was associated with subsequent revascularization especially in non-diabetic patients who underwent PCI.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- D Fujimoto
- Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan
| | - H Otake
- Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan
| | - H Kawamori
- Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan
| | - T Toba
- Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan
| | - M Nagao
- Kobe University Graduate School of Medicine, Division of Evidence-based Laboratory Medicine, Kobe, Japan
| | - Y Sugizaki
- Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan
| | - A Nagasawa
- Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan
| | - R Takeshige
- Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan
| | - A Harada
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - K Murakami
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - T Iino
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Y Irino
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - R Toh
- Kobe University Graduate School of Medicine, Division of Evidence-based Laboratory Medicine, Kobe, Japan
| | - K Hirata
- Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan
| |
Collapse
|
15
|
Salah M, Osuga S, Nakahana M, Irino Y, Shinohara M, Shimizu Y, Mukumoto N, Akasaka H, Nakaoka A, Miyawaki D, Ishihara T, Yoshida K, Okamoto Y, Sasaki R. Elucidation of gastrointestinal dysfunction in response to irradiation using metabolomics. Biochem Biophys Rep 2020; 23:100789. [PMID: 32775703 PMCID: PMC7393574 DOI: 10.1016/j.bbrep.2020.100789] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 07/01/2020] [Accepted: 07/02/2020] [Indexed: 11/29/2022] Open
Abstract
Gastrointestinal toxicity is frequently observed secondary to accidental or therapeutic radiation exposure. However, the variation in the intestinal metabolites after abdominal radiation exposure remains ambiguous. In the present study, C57BL/6 mice were exposed to 0, 2, and 20 Gy irradiation dose. The Head and chest of each mouse were covered with a lead shield before x-ray irradiation. 24 h post-irradiation treatment, intestinal tissue of each mouse was excised and prepared for metabolites measurement using gas chromatography-mass spectrometry (GC-MS). Our comprehensive analysis of metabolites in the intestinal tissues detected 44 metabolites after irradiation, including amino acids, carbohydrates, organic acids, and sugars. Amino acid levels in the intestinal tissue gradually rose, dependent on the radiation dose, perhaps as an indication of oxidative stress. Our findings raise the possibility that amino acid metabolism may be a potential target for the development of treatments to alleviate or mitigate the harmful effects of oxidative stress-related gastrointestinal toxicity due to radiation exposure. Gastrointestinal damage frequently results from radiation exposure. We analyzed the metabolic profile after local irradiation to the intestine. Amino acid levels in the intestinal tissue rose dependent on the radiation dose. Amino acid metabolism may be a good target for future therapies.
Collapse
Affiliation(s)
- Mohammed Salah
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.,Department of Biochemistry, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt
| | - Saki Osuga
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Makiko Nakahana
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Japan
| | - Masakazu Shinohara
- Division of Epidemiology and the Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Japan.,The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Japan
| | - Yasuyuki Shimizu
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Naritoshi Mukumoto
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Hiroaki Akasaka
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Ai Nakaoka
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Daisuke Miyawaki
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Takeaki Ishihara
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Kenji Yoshida
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yoshiaki Okamoto
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.,Department of Radiation Therapy, Osaka Police Hospital, Osaka, Japan
| | - Ryohei Sasaki
- Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| |
Collapse
|
16
|
Okano M, Hara T, Nishimori M, Irino Y, Satomi-Kobayashi S, Shinohara M, Toh R, Jaffer FA, Ishida T, Hirata KI. In Vivo Imaging of Venous Thrombus and Pulmonary Embolism Using Novel Murine Venous Thromboembolism Model. ACTA ACUST UNITED AC 2020; 5:344-356. [PMID: 32368694 PMCID: PMC7188875 DOI: 10.1016/j.jacbts.2020.01.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Revised: 01/08/2020] [Accepted: 01/08/2020] [Indexed: 01/27/2023]
Abstract
We established a novel clinically relevant murine DVT model at femoral/saphenous vein induced by flow restriction and light illumination. Our model newly succeeded in inducing DVT in a valve pocket and enabled spontaneous pulmonary embolism of fibrin-rich thrombus from lower extremity vein, reproducing the clinical VTE scenario. This model is suitable for motion-free in vivo high-resolution imaging of fibrin-rich DVT development and organization using 2-photon microscopy, enabling the real-time imaging of migration of platelets and leukocytes into the erythrocyte-rich DVT.
This work established a new murine venous thromboembolism (VTE) model. This model has multiple novel features representing clinical VTE that include the following: 1) deep venous thrombosis (DVT) was formed and extended in the long axis of femoral/saphenous vein; 2) thrombus was formed in a venous valve pocket; 3) deligation of suture-induced spontaneous pulmonary emboli of fibrin-rich DVT; and 4) cardiac motion-free femoral/saphenous vein allowed high-resolution intravital microscopic imaging of fibrin-rich DVT. This new model requires only commercially available epifluorescence microscopy. Therefore, this model has significant potential for better understanding of VTE pathophysiology.
Collapse
Affiliation(s)
- Mitsumasa Okano
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tetsuya Hara
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Makoto Nishimori
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Seimi Satomi-Kobayashi
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masakazu Shinohara
- Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Farouc A Jaffer
- Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.,Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
17
|
Oshita T, Toh R, Nagano Y, Kuroda K, Nagasawa Y, Harada A, Murakami K, Kiriyama M, Yoshikawa K, Miwa K, Kubo T, Iino T, Nagao M, Irino Y, Hara T, Shinohara M, Otake H, Shinke T, Nakajima K, Ishida T, Hirata KI. Association of cholesterol uptake capacity, a novel indicator for HDL functionality, and coronary plaque properties: An optical coherence tomography-based observational study. Clin Chim Acta 2020; 503:136-144. [PMID: 31972150 DOI: 10.1016/j.cca.2020.01.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2018] [Revised: 12/16/2019] [Accepted: 01/03/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND Cholesterol efflux from atherosclerotic lesion is a key function of high-density lipoprotein (HDL). Recently, we established a simple, high-throughput, cell-free assay to evaluate the capacity of HDL to accept additional cholesterol, which is herein referred to as "cholesterol uptake capacity (CUC)". OBJECTIVE To clarify the cross-sectional relationship between CUC and coronary plaque properties. METHODS We enrolled 135 patients to measure CUC and assess the morphological features of angiographic stenosis by optical coherence tomography (OCT). We estimated the extent of the lipid-rich plaque by multiplying the mean lipid arc by lipid length (lipid index). The extent of the OCT-detected macrophage accumulation in the target plaque was semi-quantitatively estimated using a grading system. RESULTS Lipid-rich plaque lesions were identified in 125 patients (92.6%). CUC was inversely associated with the lipid index (R = -0.348, P < 0.0001). In addition, CUC was also inversely associated with macrophage score (R = -0.327, P < 0.0001). Conversely, neither circulating levels of HDL cholesterol nor apoA1 showed a similar relationship. CONCLUSIONS We demonstrated that CUC was inversely related to lipid-rich plaque burden and the extent of macrophage accumulation, suggesting that CUC could be useful for cardiovascular risk stratification.
Collapse
Affiliation(s)
- Toshihiko Oshita
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - Yuichiro Nagano
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Koji Kuroda
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yoshinori Nagasawa
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Amane Harada
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | | | - Maria Kiriyama
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Keiko Yoshikawa
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Keiko Miwa
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Takuya Kubo
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Takuya Iino
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Manabu Nagao
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tetsuya Hara
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masakazu Shinohara
- Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Hiromasa Otake
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Toshiro Shinke
- Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Katsuyuki Nakajima
- Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
18
|
Tanaka K, Sasayama T, Uno T, Fujita Y, Hashiguchi M, Irino Y, Kohmura E. CBMS-07 SERINE SYNTHESIS AND ONE-CARBON METABOLISM IN GLIOMA CELLS TO SURVIVE GLUTAMINE STARVATION. Neurooncol Adv 2019. [PMCID: PMC7213390 DOI: 10.1093/noajnl/vdz039.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Cancer cells optimize nutrient utilization to supply energetic and biosynthetic pathways. These metabolic processes also include redox maintenance and epigenetic regulation through nucleic acid and protein methylation, enhancing tumorigenicity and clinical resistance. But less is known about how cancer cells exhibit metabolic flexibility to sustain cell growth and survival from nutrient starvation. Here, we identify a key role for serine availability and one-carbon metabolism in the survival of glioma cells from glutamine deprivation. To identify metabolic response to glutamine deprivation in glioma cells, we analyzed metabolites using gas chromatography and mass spectroscopy (GC/MS) in glioma cells cultured in glutamine-deprived medium and examined gene expression of key enzymes for one-carbon units using RT-PCR and western blotting methods. These expressions were also confirmed by immunohistochemical staining in glioma clinical samples Metabolome studies indicated serine, cysteine, and methionine as key differentiating amino acids between control and glutamine-deprived groups. Serine synthesis was mediated through autophagy rather than glycolysis. Gene expression analysis identified upregulation of Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) to regulate serine synthesis and one-carbon metabolism. Importantly, suppression of this metabolite impaired glioma cell survival in glutamine deprivation. In human glioma samples. MTHFD2 expressions were highest in poorly nutrient regions around “pseudopalisading necrosis”. Serine-dependent one-carbon metabolism has a key role for glioma cells to survive glutamine starvation. These results may suggest the new therapeutic strategies targeting critical glioma cells adapting the tumor microenvironment.
Collapse
Affiliation(s)
- Kazuhiro Tanaka
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takashi Sasayama
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Takiko Uno
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yuichi Fujita
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Mitsuru Hashiguchi
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuhiro Irino
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Eiji Kohmura
- Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
19
|
Sasayama T, Maeyama M, Tanaka K, Fujita Y, Hashiguchi M, Irino Y, Kohmura E. ET-12 ANTI-VEGF THERAPY WITH KETOGENIC DIET AGAINST GLIOBLASTOMA IN MOUSE MODEL. Neurooncol Adv 2019. [PMCID: PMC7213401 DOI: 10.1093/noajnl/vdz039.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
NTRODUCTUION Malignant glioma cells critically depend on glucose as the main energy source to survive and sustain their aggressive properties. The ketogenic diet (KD) has been proposed as a complementary therapy for treatment of malignant gliomas. VEGF inhibitor (bevacizumab) decreases blood supply to tumor and clinically used for glioblastoma treatment. Therefore, we examined anti-tumor effect of the combination of bevacizumab (Bev) and KD using mouse model. METHODS U87MG cells were implanted into the right brain of nude mice. One week after the implantation, mice were randomized into four treatment groups: control group, KD group, Bev group, and combination (K+B) group. KetoCal 4:1 was administered to the mice for KD. Bev (10mg/kg) was injected from tail vein twice a week. Metabolic and histological analysis of the tumor, and survival analysis of the mice were performed. RESULTS 3-hydroxy-butyrate, one of the ketone bodies, was significantly increased in the tumor of KD group, however, the metabolic enzymes of ketone bodies were not found an increased expression in immunostaining experiments. Principal component analysis (PCA) analysis demonstrated distinct clustering or a clear separation of the four groups. In K+B group, several TCA cycle-related enzymes (succinate dehydrogenase (SDH), fumarate-hydratase (FH)) were decreased, suggesting a repression of TCA cycle. In addition, several amino acids (tyrosine, valine, alanine, glutamic acid) were decreased in K+B tumor, however, alpha-ketoglutarate was significantly increased, suggesting dynamic metabolic remodeling. Histologically, Ki-67 index was most decreased in the K+B tumor among four groups. In survival analysis, Bev group had significant longer survival than control group (p=0.0016), and the K+B group had most longer survival time among four groups. CONCLUSIONS Drastic metabolic remodeling in the tumor occurred in the combination of Bev and KD This combination may be potentially useful for glioblastoma therapy.
Collapse
|
20
|
Hagihara H, Horikawa T, Irino Y, Nakamura HK, Umemori J, Shoji H, Yoshida M, Kamitani Y, Miyakawa T. Peripheral blood metabolome predicts mood change-related activity in mouse model of bipolar disorder. Mol Brain 2019; 12:107. [PMID: 31822292 PMCID: PMC6902552 DOI: 10.1186/s13041-019-0527-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2019] [Accepted: 11/26/2019] [Indexed: 12/27/2022] Open
Abstract
Bipolar disorder is a major mental illness characterized by severe swings in mood and activity levels which occur with variable amplitude and frequency. Attempts have been made to identify mood states and biological features associated with mood changes to compensate for current clinical diagnosis, which is mainly based on patients' subjective reports. Here, we used infradian (a cycle > 24 h) cyclic locomotor activity in a mouse model useful for the study of bipolar disorder as a proxy for mood changes. We show that metabolome patterns in peripheral blood could retrospectively predict the locomotor activity levels. We longitudinally monitored locomotor activity in the home cage, and subsequently collected peripheral blood and performed metabolomic analyses. We then constructed cross-validated linear regression models based on blood metabolome patterns to predict locomotor activity levels of individual mice. Our analysis revealed a significant correlation between actual and predicted activity levels, indicative of successful predictions. Pathway analysis of metabolites used for successful predictions showed enrichment in mitochondria metabolism-related terms, such as "Warburg effect" and "citric acid cycle." In addition, we found that peripheral blood metabolome patterns predicted expression levels of genes implicated in bipolar disorder in the hippocampus, a brain region responsible for mood regulation, suggesting that the brain-periphery axis is related to mood-change-associated behaviors. Our results may serve as a basis for predicting individual mood states through blood metabolomics in bipolar disorder and other mood disorders and may provide potential insight into systemic metabolic activity in relation to mood changes.
Collapse
Affiliation(s)
- Hideo Hagihara
- Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan
| | - Tomoyasu Horikawa
- Department of Neuroinformatics, ATR Computational Neuroscience Laboratories, Kyoto, 619-0288, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University, Graduate School of Medicine, Kobe, 650-0017, Japan
| | - Hironori K Nakamura
- Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan
| | - Juzoh Umemori
- Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan
| | - Hirotaka Shoji
- Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan
| | - Masaru Yoshida
- Division of Metabolomics Research, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan
| | - Yukiyasu Kamitani
- Department of Neuroinformatics, ATR Computational Neuroscience Laboratories, Kyoto, 619-0288, Japan
- Graduate School of Informatics, Kyoto University, Kyoto, 606-8501, Japan
| | - Tsuyoshi Miyakawa
- Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan.
| |
Collapse
|
21
|
Affiliation(s)
- Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
22
|
Honda T, Ohara T, Shinohara M, Hata J, Toh R, Yoshida D, Shibata M, Ishida T, Hirakawa Y, Irino Y, Sakata S, Uchida K, Kitazono T, Kanba S, Hirata KI, Ninomiya T. Serum elaidic acid concentration and risk of dementia: The Hisayama Study. Neurology 2019; 93:e2053-e2064. [PMID: 31645469 DOI: 10.1212/wnl.0000000000008464] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Accepted: 06/28/2019] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVE The associations between trans fatty acids and dementia have been unclear. We investigated the prospective association between serum elaidic acid (trans 18:1 n-9) levels, as an objective biomarker for industrial trans fat, and incident dementia and its subtypes. METHODS In total, 1,628 Japanese community residents aged 60 and older without dementia were followed prospectively from when they underwent a screening examination in 2002-2003 to November 2012 (median 10.3 years, interquartile range 7.2-10.4 years). Serum elaidic acid levels were measured using gas chromatography/mass spectrometry and divided into quartiles. The Cox proportional hazards model was used to estimate the hazard ratios for all-cause dementia, Alzheimer disease (AD), and vascular dementia by serum elaidic acid levels. RESULTS During the follow-up, 377 participants developed some type of dementia (247 AD, 102 vascular dementia). Higher serum elaidic acid levels were significantly associated with greater risk of developing all-cause dementia (p for trend = 0.003) and AD (p for trend = 0.02) after adjustment for traditional risk factors. These associations remained significant after adjustment for dietary factors, including total energy intake and intakes of saturated and polyunsaturated fatty acids (both p for trend <0.05). No significant associations were found between serum elaidic acid levels and vascular dementia. CONCLUSIONS The findings suggest that higher serum elaidic acid is a possible risk factor for the development of all-cause dementia and AD in later life. Public health policy to reduce industrially produced trans fatty acids may assist in the primary prevention of dementia.
Collapse
Affiliation(s)
- Takanori Honda
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Tomoyuki Ohara
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Masakazu Shinohara
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Jun Hata
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Ryuji Toh
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Daigo Yoshida
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Mao Shibata
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Tatsuro Ishida
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Yoichiro Hirakawa
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Yasuhiro Irino
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Satoko Sakata
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Kazuhiro Uchida
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Takanari Kitazono
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Shigenobu Kanba
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Ken-Ichi Hirata
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
| | - Toshiharu Ninomiya
- From the Departments of Epidemiology and Public Health (T.H., T.O., J.H., D.Y., M.Shibata, Y.H., S.S., T.N.), Neuropsychiatry (T.O., S.K.), Medicine and Clinical Science (J.H., Y.H., S.S., T.K.), and Psychosomatic Medicine (M.Shibata), and Center for Cohort Studies (J.H., M.Shibata, S.S., T.K., T.N.), Graduate School of Medical Sciences, Kyushu University, Fukuoka; Divisions of Epidemiology (M.Shinohara), Evidence-Based Laboratory Medicine (R.T., Y.I.), and Cardiovascular Medicine (T.I., K.-I.H.), and Integrated Center for Mass Spectrometry (M.Shinohara., Y.I.), Kobe University Graduate School of Medicine, Hyogo; and Department of Health Promotion (K.U.), School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan.
| |
Collapse
|
23
|
Nagao M, Miyashita K, Mori K, Irino Y, Toh R, Hara T, Hirata KI, Shinohara M, Nakajima K, Ishida T. Serum concentration of full-length- and carboxy-terminal fragments of endothelial lipase predicts future cardiovascular risks in patients with coronary artery disease. J Clin Lipidol 2019; 13:839-846. [PMID: 31473149 DOI: 10.1016/j.jacl.2019.07.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 06/18/2019] [Accepted: 07/21/2019] [Indexed: 10/26/2022]
Abstract
BACKGROUND Endothelial lipase (EL), a regulator of plasma high-density lipoprotein cholesterol (HDL-C), is secreted as a 68-kDa mature glycoprotein, and then cleaved by proprotein convertases. However, the clinical significance of the circulating EL fragments remains unclear. OBJECTIVE The objective of this study was to analyze the impact of serum EL fragments on HDL-C levels and major adverse cardiovascular events (MACE). METHODS Using novel monoclonal antibodies (RC3A6) against carboxy-terminal EL protein, we have established a new enzyme-linked immunosorbent assay (ELISA) system, which can detect both full-length EL protein (full EL) and carboxy-terminal truncated fragments (total EL) in serum. The previous sandwich ELISA detected only full EL. The full and total EL mass were measured in 556 patients with coronary artery disease. Among them, 272 patients who underwent coronary intervention were monitored for 2 years for MACE. RESULTS There was a significant correlation between serum full and total EL mass (R = 0.45, P < .0001). However, the total EL mass showed a stronger inverse correlation with serum HDL-cholesterol concentration than the full EL mass (R = -0.17 vs -0.02). Kaplan-Meier analysis documented an association of serum total EL mass and MACE (log-rank P = .037). When an optimal cutoff value was set at 96.23 ng/mL, total EL mass was an independent prognostic factor for MACE in the Cox proportional hazard model (HR; 1.75, 95% CI; 1.10-2.79, P = .018). CONCLUSION Serum total EL mass could be a predictor for MACE in patients with coronary artery disease. This novel ELISA will be useful for further clarifying the impact of EL on HDL metabolism and atherosclerosis.
Collapse
Affiliation(s)
- Manabu Nagao
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | | | - Kenta Mori
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Tetsuya Hara
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan; Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Masakazu Shinohara
- Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Katsuyuki Nakajima
- Laboratory of Clinical Nutrition and Medicine, Kagawa Nutrition University, Tokyo, Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| |
Collapse
|
24
|
Murakami K, Kiriyama M, Kubo T, Saiki N, Miwa K, Irino Y, Toh R, Hirata K, Harada A. Establishment Of An Automated Assay For Cholesterol Uptake Capacity, A New Concept Of High-Density Lipoprotein Functionality. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Nagano Y, Otake H, Toba T, Kuroda K, Shinkura Y, Tahara N, Tsukiyama Y, Yanaka K, Yamamoto H, Nagasawa A, Onishi H, Sugizaki Y, Takeshige R, Harada A, Murakami K, Kiriyama M, Oshita T, Irino Y, Kawamori H, Ishida T, Toh R, Shinke T, Hirata K. Impaired Cholesterol-Uptake Capacity of HDL Might Promote Target-Lesion Revascularization by Inducing Neoatherosclerosis After Stent Implantation. J Am Heart Assoc 2019; 8:e011975. [PMID: 30995875 PMCID: PMC6512103 DOI: 10.1161/jaha.119.011975] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Accepted: 03/11/2019] [Indexed: 12/17/2022]
Abstract
Background We evaluated the importance of high-density lipoprotein (HDL) functionality for target-lesion revascularization in patients treated with coronary stents using a rapid cell-free assay system to evaluate the functional capacity of HDL to accept additional cholesterol (cholesterol-uptake capacity; CUC). Methods and Results From an optical coherence tomography (OCT) registry of patients treated with coronary stents, 207 patients were enrolled and their HDL was functionally evaluated by measuring the CUC. Follow-up OCT was performed (median duration, 24.5 months after stenting) to evaluate the presence of neoatherosclerosis. Clinical follow-up was performed to assess target-lesion revascularization for a median duration of 42.3 months after stent implantation. Neoatherosclerosis was identified in 37 patients (17.9%). Multivariate logistic regression analysis revealed that a decreased CUC was independently associated with neoatherosclerosis (odds ratio, 0.799; P<0.001). The CUC showed a significant inverse correlation with incidence of target-lesion revascularization (odds ratio, 0.887; P=0.003) and with lipid accumulation inside stents, suggesting that neoatherosclerosis contributes to the association between CUC and target-lesion revascularization. Conclusions Impaired HDL functionality, detected as decreased CUC, might lead to future stent failure by provoking atherogenic changes of the neointima within stents. Both quantitative and qualitative assessments of HDL might enable the improved prediction of clinical outcomes after stent implantation.
Collapse
Affiliation(s)
- Yuichiro Nagano
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Hiromasa Otake
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Takayoshi Toba
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Koji Kuroda
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Yuto Shinkura
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Natsuko Tahara
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Yoshiro Tsukiyama
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Kenichi Yanaka
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Hiroyuki Yamamoto
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Akira Nagasawa
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Hiroyuki Onishi
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Yoichiro Sugizaki
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Ryo Takeshige
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Amane Harada
- Central Research LaboratoriesSysmex CorporationKobeJapan
| | | | - Maria Kiriyama
- Central Research LaboratoriesSysmex CorporationKobeJapan
| | - Toshihiko Oshita
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Yasuhiro Irino
- Division of Evidence‐based Laboratory MedicineKobe University Graduate School of MedicineKobeJapan
| | - Hiroyuki Kawamori
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Tatsuro Ishida
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Ryuji Toh
- Division of Evidence‐based Laboratory MedicineKobe University Graduate School of MedicineKobeJapan
| | - Toshiro Shinke
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
| | - Ken‐ichi Hirata
- Division of Cardiovascular MedicineDepartment of Internal MedicineKobe University Graduate School of MedicineKobeJapan
- Division of Evidence‐based Laboratory MedicineKobe University Graduate School of MedicineKobeJapan
| |
Collapse
|
26
|
Oshita T, Toh R, Shinohara M, Mori K, Irino Y, Nagao M, Hara T, Otake H, Ishida T, Hirata KI. Elevated Serum Elaidic Acid Predicts Risk of Repeat Revascularization After Percutaneous Coronary Intervention in Japan. Circ J 2019; 83:1032-1038. [PMID: 30867359 DOI: 10.1253/circj.cj-18-1175] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Trans-fatty acid (TFA) intake increases the risk of coronary artery disease (CAD). Our previous cross-sectional survey showed that middle-aged patients with CAD in Japan have elevated serum TFA. In this study, we longitudinally investigated whether elevated TFA is a risk factor in the secondary prevention of CAD for the same-age patients. Methods and Results: A total of 112 patients (age, 21-66 years) who underwent percutaneous coronary intervention were followed up for up to 2 years. Serum elaidic acid was measured using gas chromatography/mass spectrometry as a marker of TFA intake and divided into quartiles. The primary endpoint was ischemia-driven target lesion revascularization (TLR). The hazard ratio (HR) for TLR increased significantly with higher serum elaidic acid (P<0.01). The significant positive trend remained unchanged after adjusting for conventional lipid profile and bare-metal stent usage. In contrast, although triglycerides and low-density lipoprotein cholesterol were positively correlated with elaidic acid, they were not associated with TLR. On multivariable Cox proportional hazard analysis, elevated elaidic acid was independently associated with TLR risk after adjusting for conventional coronary risks (HR, 10.7, P<0.01). CONCLUSIONS Elevated elaidic acid is associated with higher TLR rate in middle-aged patients with CAD, suggesting that excessive TFA intake is becoming a serious health problem in Japan.
Collapse
Affiliation(s)
- Toshihiko Oshita
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| | | | - Kenta Mori
- Department of General Internal Medicine, Kobe University Hospita
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Manabu Nagao
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Tetsuya Hara
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Hiromasa Otake
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine.,Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| |
Collapse
|
27
|
Matsuo K, Hosoda K, Tanaka J, Yamamoto Y, Imahori T, Nakai T, Irino Y, Shinohara M, Sasayama T, Kohmura E. Abstract WP342: Activate the Pentose Phosphate Pathway to Reduce the Cerebral Ischemia/Reperfusion Injury: The Impact of Heat Shock Protein 27 Phosphorylation. Stroke 2019. [DOI: 10.1161/str.50.suppl_1.wp342] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
Based on metabolomics with gas chromatography-mass spectrometry, we showed that pentose phosphate pathway (PPP) is activated during cerebral ischemia and reperfusion in rat cerebral cortex. Especially, heat shock protein 27 (HSP27) phosphorylation seems to play an important role in activating glucose 6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in PPP. To confirm the hypothesis that HSP27 phosphorylation can be a potential target for the treatment of ischemic stroke, we used KU55933 and geranylgeranylacetone (GGA). KU55933 is the inhibitor of ataxia telangiectasia mutated kinase (ATMK), inhibiting the phosphorylation of HSP27. GGA can induce the expression of HSP families in various organs.
Methods:
First, 10 μl of KU55933 or DMSO was injected into the lateral ventricle of male Wistar rats (n=5 each). One hour after the injection, 1.5-h middle cerebral artery occlusion (MCAO) and following 24-h reperfusion were performed to evaluate the effect. Next, intracerebroventricular (ICV) injection of 10 μl of GGA or DMSO was performed 3-h prior to 1-h MCAO/24-h reperfusion. Infarct size, immunoblotting, G6PD activity, and protein carbonyl indicating protein oxidation, were examined.
Results:
ICV injection of KU-55933 significantly reduced the phosphorylated HSP27 (pHSP27) and G6PD activity (Fig. 1A and B). In addition, it increased the infarct size and the protein carbonyl (Fig. 1 C and D). In contrast, ICV injection of GGA increased both HSP27 and pHSP27, which resulted in significant reduction of the infarct size (19.9% vs 31.3%, p<0.01) (Fig. 1 E and F).
Conclusions:
ATMK contribute the antioxidative effect with phosphorylation of HSP27 during cerebral ischemia/reperfusion. GGA may be a potential therapeutic drug for ischemic stroke. Further studies are required prior to clinical application, including investigation that use more convenient route of administration; and that evaluate the effect of GGA administration after MCAO.
Collapse
Affiliation(s)
- Kazuya Matsuo
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | | | - Jun Tanaka
- Neurosurgery, Kita-harima Med Cntr, Ono, Japan
| | - Yusuke Yamamoto
- Neurosurgery, Hyogo Brain and Heart Cntr at Himeji, Himeji, Japan
| | | | - Tomoaki Nakai
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | - Yasuhiro Irino
- Div of Evidence-based Laboratory Medicine, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | - Masakazu Shinohara
- The Integrated Cntr for Mass Spectrometry, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | | | - Eiji Kohmura
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| |
Collapse
|
28
|
Hayashi T, Yamashita T, Watanabe H, Kami K, Yoshida N, Tabata T, Emoto T, Sasaki N, Mizoguchi T, Irino Y, Toh R, Shinohara M, Okada Y, Ogawa W, Yamada T, Hirata KI. Gut Microbiome and Plasma Microbiome-Related Metabolites in Patients With Decompensated and Compensated Heart Failure. Circ J 2018; 83:182-192. [DOI: 10.1253/circj.cj-18-0468] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Tomohiro Hayashi
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Tomoya Yamashita
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Hikaru Watanabe
- School of Life Science and Technology, Tokyo Institute of Technology
| | | | - Naofumi Yoshida
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Tokiko Tabata
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Takuo Emoto
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Naoto Sasaki
- Department of Medical Pharmaceutics, Kobe Pharmaceutical University
| | - Taiji Mizoguchi
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Masakazu Shinohara
- Division of Epidemiology and The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine
| | - Yuko Okada
- Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Wataru Ogawa
- Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Takuji Yamada
- School of Life Science and Technology, Tokyo Institute of Technology
| | - Ken-ichi Hirata
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| |
Collapse
|
29
|
Maeyama M, Sasayama T, Tanaka K, Irino Y, Nishihara M, Tanaka H, Nakamizo S, Kohmura E. CBMT-25. ANTI-TUMOR EFFECT OF VEGF INHIBITOR PLUS KETOGENIC DIET THERAPY FOR GLIOBLASTOMA. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | | | - Yasuhiro Irino
- Division of Evidenced-Based Laboratory Medicine, Kobe University, Kobe, Japan
| | | | | | | | - Eiji Kohmura
- Department of Neurosurgery, Kobe University, Kobe, Japan
| |
Collapse
|
30
|
Tanaka K, Sasayama T, Uno T, Maeyama M, Fujita Y, Irino Y, Kohmura E. CBMT-10. GLUTAMINE DEPRIVATION ALTERS ONE-CARBON METABOLISM TO MAINTAIN GLIOMA CELL SURVIVAL. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | - Takiko Uno
- Department of Neurosurgery, Kobe University, Kobe, Japan
| | | | - Yuichi Fujita
- Department of Neurosurgery, Kobe University, Kobe, Japan
| | - Yasuhiro Irino
- Division of Evidenced-based Laboratory Medicine, Kobe University, Kobe, Japan
| | - Eiji Kohmura
- Department of Neurosurgery, Kobe University, Kobe, Japan
| |
Collapse
|
31
|
Shiomi M, Takeda H, Irino Y, Yamada S, Kuniyoshi N, Ying Y, Koike T, Izumi Y, Shinohara M, Bamba T, Ishida T. Development of markers for progression of coronary plaques using WHHLMI rabbits, an animal model of familial hypercholesterolemia. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Yamamoto Y, Hosoda K, Imahori T, Tanaka J, Matsuo K, Nakai T, Irino Y, Shinohara M, Sato N, Sasayama T, Tanaka K, Nagashima H, Kohta M, Kohmura E. Pentose phosphate pathway activation via HSP27 phosphorylation by ATM kinase: A putative endogenous antioxidant defense mechanism during cerebral ischemia-reperfusion. Brain Res 2018; 1687:82-94. [PMID: 29510140 DOI: 10.1016/j.brainres.2018.03.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 02/24/2018] [Accepted: 03/01/2018] [Indexed: 11/19/2022]
Abstract
Molecular mechanism underlying ischemic stroke remains poorly understood. We previously reported glucose 6-phosphate dehydrogenase (G6PD) activity in pentose phosphate pathway (PPP) is activated via heat shock protein 27 (HSP27) phosphorylation at serine 85 (S85) by ataxia telangiectasia mutated (ATM) kinase during cerebral ischemia. This mechanism seems to be endogenous antioxidative system. To determine whether this system also works during reperfusion, we performed comparative metabolic analysis of reperfusion effect on metabolism in rat cortex using middle cerebral artery occlusion (MCAO). Metabolic profiling using gas-chromatography/mass-spectrometry analysis showed changes in metabolic state that depended on reperfusion time. Enrichment analysis showed PPP was significantly upregulated during ischemia-reperfusion. Significant increases in fructose 6-phosphate and ribulose 5-phosphate after reperfusion also suggested enhancement of PPP. In relation to PPP, ischemia-reperfusion induced an increase of up to 69-fold in HSP27 transcripts after 24-h reperfusion. Immunoblotting showed gradual increase in HSP27 protein and marked increase in HSP27 phosphorylation (S85) that were time-dependent (4.5-fold after 24-h reperfusion). G6PD activity was significantly elevated after 1-h MCAO (20%), reduced after 1-h reperfusion, increased gradually thereafter and significantly elevated after 24-h reperfusion. The NADPH/NAD+ ratio displayed similar increasing pattern. Intracerebroventricular injection of ATM kinase inhibitor (KU-55933) significantly reduced HSP27 phosphorylation and G6PD activity, significantly increased protein carbonyl, and resulted in increase in infarct size (100%) 24-h after reperfusion following 90-min MCAO. Consequently, G6PD activation via HSP27 phosphorylation by ATM kinase may be part of endogenous antioxidant defense neuroprotection mechanism that is activated during ischemia-reperfusion. These findings have important implications for treatment of stroke.
Collapse
Affiliation(s)
- Yusuke Yamamoto
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Kohkichi Hosoda
- Department of Neurosurgery, Kobe City Nishi-Kobe Medical Center, 5-7-1, Kojidai, Nishi-ku, Kobe 651-2273, Japan.
| | - Taichiro Imahori
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Jun Tanaka
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Kazuya Matsuo
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Tomoaki Nakai
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Masakazu Shinohara
- Division of Epidemiology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Naoko Sato
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Takashi Sasayama
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Kazuhiro Tanaka
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Hiroaki Nagashima
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Masaaki Kohta
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Eiji Kohmura
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| |
Collapse
|
33
|
Shoji H, Irino Y, Yoshida M, Miyakawa T. Behavioral effects of long-term oral administration of aluminum ammonium sulfate in male and female C57BL/6J mice. Neuropsychopharmacol Rep 2018; 38:18-36. [PMID: 30106265 PMCID: PMC7292291 DOI: 10.1002/npr2.12002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Revised: 11/27/2017] [Accepted: 11/27/2017] [Indexed: 12/18/2022] Open
Abstract
Background Aluminum (Al) is considered to be a neurotoxic metal, and excessive exposure to Al has been reported to be a potential risk factor for neurodegenerative diseases. Al ammonium sulfate is one of the Al compounds that is widely used as a food additive. However, the effects of the oral administration of Al ammonium sulfate on physical development and behavior remain to be examined. Methods In this study, we investigated the effects of the administration of Al ammonium sulfate 12‐water dissolved in drinking water (0.075 mg/mL) beginning in adolescence on various types of behavior in adult female C57BL/6J mice through a battery of behavioral tests (low‐dose experiment; Experiment 1). We further examined the behavioral effects of the oral administration of a higher dose of the Al compound in drinking water (1 mg/mL) beginning in the prenatal period on behavior in adult male and female mice (high‐dose experiment; Experiment 2). Results In the low‐dose experiment, in which females’ oral intake of Al was estimated to be 0.97 mg Al/kg/d as adults, Al‐treated females exhibited an increase in total arm entries in the elevated plus maze test, an initial decrease and subsequent increase in immobility in the forced swim test, and reduced freezing in the fear conditioning test approximately 1 month after the conditioning session compared with vehicle‐treated females (uncorrected P < .05). However, the behavioral differences did not reach a statistically significant level after correction for multiple testing. In the high‐dose experiment, in which animals’ oral intakes were estimated to be about ten times higher than those in the low‐dose experiment, behavioral differences found in the low‐dose experiment were not observed in high‐dose Al‐treated mice, suggesting that the results of the low‐dose experiment might be false positives. Additionally, although high‐dose Al‐treated females exhibited increased social contacts with unfamiliar conspecifics and impaired reference memory performance, and high‐dose Al‐treated mice exhibited decreases in prepulse inhibition and in correct responses in the working memory task (uncorrected P < .05), the differences in any of the behavioral measures did not reach the significance level after correction for multiple testing. Conclusion Our results show that long‐term oral exposure to Al ammonium sulfate at the doses used in this study may have the potential to induce some behavioral changes in C57BL/6J mice. However, the behavioral effects of Al were small and statistically weak, as indicated by the fact that the results failed to reach the study‐wide significance level. Thus, further study will be needed to replicate the results and reevaluate the behavioral outcomes of oral intake of Al ammonium sulfate. Aluminum (Al) ammonium sulfate was orally administered to C57BL/6J mice (estimated dose of 0.97‐9.78 Al mg/kg/d). Behavioral effects of Al were assessed in a battery of behavioral tests in mice in adulthood. Statistically significant behavioral differences were not found between Al‐ and vehicle‐treated mice.
![]()
Collapse
Affiliation(s)
- Hirotaka Shoji
- Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan
| | - Yasuhiro Irino
- Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masaru Yoshida
- Division of Metabolomics Research, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.,Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tsuyoshi Miyakawa
- Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake, Japan
| |
Collapse
|
34
|
Nagao M, Toh R, Irino Y, Nakajima H, Oshita T, Tsuda S, Hara T, Shinohara M, Ishida T, Hirata KI. High-density lipoprotein protects cardiomyocytes from oxidative stress via the PI3K/mTOR signaling pathway. FEBS Open Bio 2017; 7:1402-1409. [PMID: 28904868 PMCID: PMC5586351 DOI: 10.1002/2211-5463.12279] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Revised: 06/26/2017] [Accepted: 07/23/2017] [Indexed: 02/07/2023] Open
Abstract
Low levels of plasma high-density lipoprotein (HDL) cholesterol are associated with an increased risk of heart failure, regardless of the presence or absence of coronary artery disease. However, the direct effects of HDL on failing myocardium have not been fully elucidated. We found that HDL treatment resulted in improved cell viability in H9c2 cardiomyocytes under oxidative stress. This cardioprotective effect of HDL was regulated via the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. mTOR signaling promotes cell survival through the inactivation of the BCL2-associated agonist of cell death via phosphorylation of ribosomal protein S6 kinase. Modulation of cardiac PI3K/mTOR signaling by HDL could represent a novel therapeutic strategy for heart failure.
Collapse
Affiliation(s)
- Manabu Nagao
- Division of Cardiovascular Medicine Kobe University Graduate School of Medicine Japan
| | - Ryuji Toh
- Division of Evidence-Based Laboratory Medicine Kobe University Graduate School of Medicine Japan
| | - Yasuhiro Irino
- Division of Evidence-Based Laboratory Medicine Kobe University Graduate School of Medicine Japan
| | - Hideto Nakajima
- Division of Cardiovascular Medicine Kobe University Graduate School of Medicine Japan
| | - Toshihiko Oshita
- Division of Cardiovascular Medicine Kobe University Graduate School of Medicine Japan
| | - Shigeyasu Tsuda
- Division of Cardiovascular Medicine Kobe University Graduate School of Medicine Japan
| | - Tetsuya Hara
- Division of Cardiovascular Medicine Kobe University Graduate School of Medicine Japan
| | - Masakazu Shinohara
- Division of Epidemiology Kobe University Graduate School of Medicine Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine Kobe University Graduate School of Medicine Japan
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine Kobe University Graduate School of Medicine Japan.,Division of Evidence-Based Laboratory Medicine Kobe University Graduate School of Medicine Japan
| |
Collapse
|
35
|
Imahori T, Hosoda K, Nakai T, Yamamoto Y, Irino Y, Shinohara M, Sato N, Sasayama T, Tanaka K, Nagashima H, Kohta M, Kohmura E. Corrigendum to “Combined metabolic and transcriptional profiling identifies pentose phosphate pathway activation by HSP27 phosphorylation during cerebral ischemia” [Neuroscience 349 (2017) 1–16]. Neuroscience 2017; 357:414. [DOI: 10.1016/j.neuroscience.2017.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Hara T, Monguchi T, Iwamoto N, Akashi M, Mori K, Oshita T, Okano M, Toh R, Irino Y, Shinohara M, Yamashita Y, Shioi G, Furuse M, Ishida T, Hirata KI. Targeted Disruption of JCAD (Junctional Protein Associated With Coronary Artery Disease)/KIAA1462, a Coronary Artery Disease-Associated Gene Product, Inhibits Angiogenic Processes In Vitro and In Vivo. Arterioscler Thromb Vasc Biol 2017; 37:1667-1673. [PMID: 28705794 DOI: 10.1161/atvbaha.117.309721] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2016] [Accepted: 06/30/2017] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Recent genome-wide association studies newly identified the human KIAA1462 gene as a new locus for coronary artery disease. However, the function of the gene product, named JCAD (junctional protein associated with coronary artery disease), is unknown. Because JCAD is expressed at cell-cell junctions in endothelial cells, we hypothesized and tested whether JCAD regulates angiogenic processes in vitro and in vivo. APPROACH AND RESULTS Cell culture experiments revealed impaired angiogenic ability (proliferation, migration, and cord formation) by the knockdown of JCAD with siRNA (P<0.05 versus control siRNA). We have generated mice lacking JCAD (mKIAA1462-/-) by gene-targeted deletion of JCAD to address in vivo angiogenic function. mKIAA1462-/- mice did not show morphological differences in development of retinal vasculature. Ex vivo aortic ring model demonstrated impaired neovascularization in aorta from mKIAA1462-/- mice than control wild-type mice (P<0.05). Tumor growth was assessed by monitoring tumor volume after the subcutaneous injection of melanoma, LLC (Lewis lung carcinoma), and E0771 cells into the mice. mKIAA1462-/- mice exhibited significantly smaller tumor volume compared with wild-type mice (P<0.001). Histological assessment of the tumor exhibited less smooth muscle actin-positive neovascularization determined by CD31-positive vascular structure in tumor of mKIAA1462-/- mice than wild-type mice, indicating that knockdown of JCAD inhibited the vascular maturation in pathological angiogenic process. CONCLUSIONS These in vitro and in vivo studies suggest that JCAD has a redundant functional role in physiological angiogenesis but serves a pivotal role in pathological angiogenic process after birth.
Collapse
MESH Headings
- Animals
- Carcinoma, Lewis Lung/blood supply
- Carcinoma, Lewis Lung/genetics
- Carcinoma, Lewis Lung/metabolism
- Cell Adhesion Molecules/deficiency
- Cell Adhesion Molecules/genetics
- Cell Adhesion Molecules/metabolism
- Cell Movement
- Cell Proliferation
- Cells, Cultured
- Endothelial Cells/metabolism
- Genotype
- Human Umbilical Vein Endothelial Cells/metabolism
- Intercellular Junctions/metabolism
- Melanoma, Experimental/blood supply
- Melanoma, Experimental/genetics
- Melanoma, Experimental/metabolism
- Mice, Inbred C57BL
- Mice, Knockout
- Neovascularization, Pathologic
- Neovascularization, Physiologic
- Phenotype
- RNA Interference
- Retinal Neovascularization
- Signal Transduction
- Time Factors
- Tissue Culture Techniques
- Transfection
- Tumor Burden
Collapse
Affiliation(s)
- Tetsuya Hara
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.).
| | - Tomoko Monguchi
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Noriko Iwamoto
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Masaya Akashi
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Kenta Mori
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Toshihiko Oshita
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Mitsumasa Okano
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Ryuji Toh
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Yasuhiro Irino
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Masakazu Shinohara
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Yui Yamashita
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Go Shioi
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Mikio Furuse
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Tatsuro Ishida
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| | - Ken-Ichi Hirata
- From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.H., T.M., K.M., T.O., M.O., T.I., K.-i.H.), Division of Cell Biology, Department of Physiology and Cell Biology (N.I., M.A., M.F.), Department of Oral and Maxillofacial Surgery (M.A.), Division of Evidence-Based Laboratory Medicine (R.T., Y.I.), Division of Integrated Medical Education, Department of Community Medicine and Social Healthcare Science (M.S.), and The Integrated Center for Mass Spectrometry (M.S.), Kobe University Graduate School of Medicine, Japan; Animal Resource Development Unit (Y.Y.) and Genetic Engineering Team (Y.Y., G.S.), RIKEN Center for Life Science Technologies, Kobe, Hyogo, Japan; and Division of Cell Structure, National Institute for Physiological Sciences, Okazaki, Aichi, Japan (M.F.)
| |
Collapse
|
37
|
Tanaka N, Irino Y, Shinohara M, Tsuda S, Mori T, Nagao M, Oshita T, Mori K, Hara T, Toh R, Ishida T, Hirata KI. Eicosapentaenoic Acid-Enriched High-Density Lipoproteins Exhibit Anti-Atherogenic Properties. Circ J 2017; 82:596-601. [PMID: 28652532 DOI: 10.1253/circj.cj-17-0294] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND It has previously been reported that oral administration of purified eicosapentaenoic acid (EPA) generates EPA-rich high-density lipoprotein (HDL) particles with a variety of anti-inflammatory properties. In this study, the mechanism underlying the anti-atherogenic effects of EPA-rich HDL using reconstituted HDL (rHDL) was investigated.Methods and Results:rHDL was generated by the sodium cholate dialysis method, using apolipoprotein A-1 protein, cholesterol, and various concentrations of EPA-phosphatidylcholine (PC) or egg-PC. Increased EPA-PC contents in rHDL resulted in decreased particle size. Next, the effects of rHDL containing various amounts (0-100% of total PC) of EPA-PC on vascular cell adhesion molecule-1 (VCAM-1) expression in human umbilical vein endothelial cells (HUVECs) was examined. Cytokine-stimulated VCAM-1 expression was inhibited in a dose-dependent manner based on the amount of EPA-PC in rHDL. Surprisingly, the incubation of HUVECs with EPA-rich rHDL resulted in the production of resolvin E3 (RvE3), an anti-inflammatory metabolite derived from EPA. Incubation with EPA-PC alone did not adequately induce RvE3 production, suggesting that RvE3 production requires an endothelial cell-HDL interaction. The increased anti-inflammatory effects of EPA-rich HDL may be explained by EPA itself and RvE3 production. Furthermore, the increase in EPA-PC content enhanced cholesterol efflux. CONCLUSIONS The EPA-enriched HDL particles exhibit cardioprotective properties via the production of anti-inflammatory lipid metabolites and the increase in cholesterol efflux.
Collapse
Affiliation(s)
- Nobuaki Tanaka
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine.,The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine
| | - Masakazu Shinohara
- The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine.,Division of Epidemiology, Kobe University Graduate School of Medicine
| | - Shigeyasu Tsuda
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Takeshige Mori
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Manabu Nagao
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Toshihiko Oshita
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Kenta Mori
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Tetsuya Hara
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine.,Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine
| |
Collapse
|
38
|
Harada A, Toh R, Murakami K, Kiriyama M, Yoshikawa K, Miwa K, Kubo T, Irino Y, Mori K, Tanaka N, Nishimura K, Ishida T, Hirata KI. Cholesterol Uptake Capacity: A New Measure of HDL Functionality for Coronary Risk Assessment. J Appl Lab Med 2017; 2:186-200. [PMID: 32630971 DOI: 10.1373/jalm.2016.022913] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Accepted: 03/28/2017] [Indexed: 11/06/2022]
Abstract
BACKGROUND Recent studies have shown that the cholesterol efflux capacity of HDL is a better predictor of cardiovascular disease (CVD) than HDL cholesterol. However, the standard procedures used for measuring cholesterol efflux capacity involve radioisotope-labeled cholesterol and cultured macrophages. Thus, a simpler method to measure HDL functionality is needed for clinical application. METHODS We established a cell-free assay system to evaluate the capacity of HDL to accept additional cholesterol, which we named cholesterol "uptake capacity," using fluorescently labeled cholesterol and an anti-apolipoprotein A1 antibody. We quantified cholesterol uptake capacity of apolipoprotein B (apoB)-depleted serum samples from patients with coronary artery disease who had previously undergone revascularization. RESULTS This assay system exhibited high reproducibility (CV <10%) and a short processing time (<6 h). The myeloperoxidase-mediated oxidation of apoB-depleted serum impaired cholesterol uptake capacity. Cholesterol uptake capacity correlated significantly with cholesterol efflux capacity (r2 = 0.47, n = 30). Furthermore, cholesterol uptake capacity correlated inversely with the requirement for revascularization because of recurrence of coronary lesions in patients with optimal control of LDL cholesterol (P < 0.01, n = 156). A multivariate analysis adjusted for traditional coronary risk factors showed that only cholesterol uptake capacity remained significant (odds ratio, 0.48; 95% CI, 0.29-0.80; P = 0.0048). CONCLUSIONS Cholesterol uptake capacity assay evaluates the functionality of HDL in a sensitive and high-throughput manner without using radioisotope label and cells. This assay system could be used for the assessment of CVD risk in the clinical settings.
Collapse
Affiliation(s)
- Amane Harada
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Ryuji Toh
- Division of Evidence-Based Laboratory Medicine and
| | | | - Maria Kiriyama
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Keiko Yoshikawa
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Keiko Miwa
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | - Takuya Kubo
- Central Research Laboratories, Sysmex Corporation, Kobe, Japan
| | | | - Kenta Mori
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Nobuaki Tanaka
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kunihiro Nishimura
- Department of Preventive Medicine and Epidemiologic Informatics, Office of Evidence-Based Medicine and Risk Analysis, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ken-Ichi Hirata
- Division of Evidence-Based Laboratory Medicine and.,Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| |
Collapse
|
39
|
Itcho K, Yoshii Y, Ohno H, Oki K, Shinohara M, Irino Y, Toh R, Ishida T, Hirata KI, Yoneda M. Association between Serum Elaidic Acid Concentration and Insulin Resistance in Two Japanese Cohorts with Different Lifestyles. J Atheroscler Thromb 2017; 24:1206-1214. [PMID: 28484112 PMCID: PMC5742366 DOI: 10.5551/jat.39164] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Aim: Many cohort studies have shown that increased trans fatty acid (TFA) intake increases the risk of developing coronary heart disease. However, whether TFA intake is directly associated with the development of diabetes mellitus (DM) remains unknown. Methods: We performed the 75-g oral glucose tolerance test in two Japanese cohorts: a cohort of 454 native Japanese living in Hiroshima, Japan, and a cohort of 426 Japanese-Americans living in Los Angeles, USA, who shared identical genetic predispositions but had different lifestyles. Serum elaidic acid concentration was measured and compared, and its association with insulin resistance was assessed. Results: Serum elaidic acid concentrations were significantly higher in the Japanese-Americans (median, 18.2 µmol/L) than in the native Japanese (median, 11.0 µmol/L). The serum elaidic acid concentrations in the native Japanese DM group (16.0 µmol/L) were significantly higher compared with those in the normal glucose tolerance (10.8 µmol/L) and impaired glucose tolerance (11.7 µmol/L) groups. Multiple linear regression analyses showed that serum elaidic acid concentrations were significantly positively associated with homeostasis model assessment for insulin resistance (HOMA-IR) values after adjusting for various factors. Conclusions: These results suggest that excessive TFA intake worsens insulin resistance and increases the risk of developing DM even in the native Japanese, whose intakes of animal fat and simple carbohydrates were presumed to be lower than those of the Japanese-Americans.
Collapse
Affiliation(s)
- Kiyotaka Itcho
- Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University
| | - Yoko Yoshii
- Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University
| | - Haruya Ohno
- Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University
| | - Kenji Oki
- Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University
| | - Masakazu Shinohara
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Yasuhiro Irino
- Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Ryuji Toh
- Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Masayasu Yoneda
- Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University
| |
Collapse
|
40
|
Takahashi S, Saegusa J, Sendo S, Okano T, Akashi K, Irino Y, Morinobu A. Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 2017; 19:76. [PMID: 28399896 PMCID: PMC5387190 DOI: 10.1186/s13075-017-1283-3] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 03/24/2017] [Indexed: 01/08/2023] Open
Abstract
Background The recent findings of cancer-specific metabolic changes, including increased glucose and glutamine consumption, have provided new therapeutic targets for consideration. Fibroblast-like synoviocytes (FLS) from rheumatoid arthritis (RA) patients exhibit several tumor cell-like characteristics; however, the role of glucose and glutamine metabolism in the aberrant proliferation of these cells is unclear. Here, we evaluated the role of these metabolic pathways in RA-FLS proliferation and in autoimmune arthritis in SKG mice. Methods The expression of glycolysis- or glutaminolysis-related enzymes was evaluated by real-time polymerase chain reaction (PCR) and Western blotting, and the intracellular metabolites were evaluated by metabolomic analyses. The effects of glucose or glutamine on RA-FLS cell growth were investigated using glucose- or glutamine-free medium. Glutaminase (GLS)1 small interfering RNA (siRNA) and the GLS1 inhibitor compound 968 were used to inhibit GLS1 in RA-FLS, and compound 968 was used to study the effect of GLS1 inhibition in zymosan A-injected SKG mice. Results GLS1 expression was increased in RA-FLS, and metabolomic analyses revealed that glutamine metabolism was increased in RA-FLS. RA-FLS proliferation was reduced under glutamine-deprived, but not glucose-deprived, conditions. Cell growth of RA-FLS was inhibited by GLS1 siRNA transfection or GLS1 inhibitor treatment. Treating RA-FLS with either interleukin-17 or platelet-derived growth factor resulted in increased GLS1 levels. Compound 968 ameliorated the autoimmune arthritis and decreased the number of Ki-67-positive synovial cells in SKG mice. Conclusions Our results suggested that glutamine metabolism is involved in the pathogenesis of RA and that GLS1 plays an important role in regulating RA-FLS proliferation, and may be a novel therapeutic target for RA. Electronic supplementary material The online version of this article (doi:10.1186/s13075-017-1283-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Soshi Takahashi
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan
| | - Jun Saegusa
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan. .,Department of Clinical Laboratory, Kobe University Hospital, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan.
| | - Sho Sendo
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan
| | - Takaichi Okano
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan
| | - Kengo Akashi
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan
| | - Yasuhiro Irino
- Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan
| | - Akio Morinobu
- Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan
| |
Collapse
|
41
|
Imahori T, Hosoda K, Nakai T, Yamamoto Y, Irino Y, Shinohara M, Sato N, Sasayama T, Tanaka K, Nagashima H, Kohta M, Kohmura E. Combined metabolic and transcriptional profiling identifies pentose phosphate pathway activation by HSP27 phosphorylation during cerebral ischemia. Neuroscience 2017; 349:1-16. [PMID: 28257891 DOI: 10.1016/j.neuroscience.2017.02.036] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2016] [Revised: 02/10/2017] [Accepted: 02/17/2017] [Indexed: 12/28/2022]
Abstract
The metabolic pathophysiology underlying ischemic stroke remains poorly understood. To gain insight into these mechanisms, we performed a comparative metabolic and transcriptional analysis of the effects of cerebral ischemia on the metabolism of the cerebral cortex using middle cerebral artery occlusion (MCAO) rat model. Metabolic profiling by gas-chromatography/mass-spectrometry analysis showed clear separation between the ischemia and control group. The decreases of fructose 6-phosphate and ribulose 5-phosphate suggested enhancement of the pentose phosphate pathway (PPP) during cerebral ischemia (120-min MCAO) without reperfusion. Transcriptional profiling by microarray hybridization indicated that the Toll-like receptor and mitogen-activated protein kinase (MAPK) signaling pathways were upregulated during cerebral ischemia without reperfusion. In relation to the PPP, upregulation of heat shock protein 27 (HSP27) was observed in the MAPK signaling pathway and was confirmed through real-time polymerase chain reaction. Immunoblotting showed a slight increase in HSP27 protein expression and a marked increase in HSP27 phosphorylation at serine 85 after 60-min and 120-min MCAO without reperfusion. Corresponding upregulation of glucose 6-phosphate dehydrogenase (G6PD) activity and an increase in the NADPH/NAD+ ratio were also observed after 120-min MCAO. Furthermore, intracerebroventricular injection of ataxia telangiectasia mutated (ATM) kinase inhibitor (KU-55933) significantly reduced HSP27 phosphorylation and G6PD upregulation after MCAO, but that of protein kinase D inhibitor (CID755673) did not affect HSP27 phosphorylation. Consequently, G6PD activation via ischemia-induced HSP27 phosphorylation by ATM kinase may be part of an endogenous antioxidant defense neuroprotection mechanism during the earliest stages of ischemia. These findings have important therapeutic implications for the treatment of stroke.
Collapse
Affiliation(s)
- Taichiro Imahori
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Kohkichi Hosoda
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
| | - Tomoaki Nakai
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Yusuke Yamamoto
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Masakazu Shinohara
- The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan; Division of Epidemiology, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Naoko Sato
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Takashi Sasayama
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Kazuhiro Tanaka
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Hiroaki Nagashima
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Masaaki Kohta
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| | - Eiji Kohmura
- Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
| |
Collapse
|
42
|
Monguchi T, Hara T, Hasokawa M, Nakajima H, Mori K, Toh R, Irino Y, Ishida T, Hirata KI, Shinohara M. Excessive intake of trans fatty acid accelerates atherosclerosis through promoting inflammation and oxidative stress in a mouse model of hyperlipidemia. J Cardiol 2017; 70:121-127. [PMID: 28254384 DOI: 10.1016/j.jjcc.2016.12.012] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 12/19/2016] [Accepted: 12/25/2016] [Indexed: 12/12/2022]
Abstract
BACKGROUND Epidemiological studies have demonstrated that trans fatty acids (TFAs) are a risk for coronary artery disease. However, the precise mechanism underlying the proatherogenic effect of TFA has not been completely elucidated. To obtain better understanding of the impact of TFA on vascular diseases, this study investigated the effect of TFA on oxidative stress using a mouse model of atherosclerosis. METHODS Low-density lipoprotein (LDL) receptor knockout mice were fed with diet containing 0.5% cholesterol (control), 0.5% cholesterol+5% elaidic acids (Trans group), and 0.5% cholesterol+5% oleic acids (Cis group) for 8 weeks. Atherosclerotic lesion and oxidative stress in aortic wall were evaluated. In vitro experiments using smooth muscle cells were performed to corroborate in vivo findings. RESULTS The atherosclerotic lesion area was significantly larger in Trans group than that in control or Cis group. Lipoprotein fractionation was similar among groups, while plasma oxidized LDL level and superoxide production in the vessel wall were markedly increased in Trans group. Elaidic acids were accumulated in a variety of tissues including liver and adipose tissue, which was associated with the high level of inflammatory cytokines in these tissues and plasma. Aortic wall from Trans group showed augmented expression of reactive oxygen species and NAPDH oxidase (p22phox) in smooth muscle cells. In vitro experiments confirmed that elaidic acids upregulated expression of NADPH oxidase and inflammatory cytokines in cultured smooth muscle cells. CONCLUSION Excessive intake of TFA contributes to the progression of atherosclerosis by evoking inflammation and oxidative stress in mice.
Collapse
Affiliation(s)
- Tomoko Monguchi
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tetsuya Hara
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - Minoru Hasokawa
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Hideto Nakajima
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Kenta Mori
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ryuji Toh
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Yasuhiro Irino
- Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Masakazu Shinohara
- Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe, Japan; The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Kobe, Japan.
| |
Collapse
|
43
|
Yamamoto Y, Hosoda K, Imahori T, Irino Y, Shinohara M, Tanaka J, Nakai T, Sato N, Kohmura E. Abstract WMP77: Combination of Metabolic and Transcriptional Profiling Identifies Pentose Phosphate Pathway Activation by Heat Shock Protein 27 Phosphorylation During Cerebral Ischemia. Stroke 2017. [DOI: 10.1161/str.48.suppl_1.wmp77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives:
The metabolic pathophysiology of ischemic stroke remains poorly understood. We performed a comparative omics analysis to identify the effects of cerebral ischemia on metabolism of cerebral cortex in the rat model with middle cerebral artery occlusion (MCAO).
Methods:
MCAO was induced with suture occlusion technique. After the desired period of MCAO (30, 60, 120min), the rats were sacrificed. Tissue samples from the ischemic lesion were collected. Sham operated rats were treated in the same way except MCAO. Water-soluble metabolites were extracted and measured by gas-chromatography/mass-spectrometry (GC/MS). The obtained data were analyzed using multivariate statistics to explore metabolic pathways involved in ischemia. The associated metabolic enzymes were investigated with real-time polymerase chain reaction (RT-PCR) and Immunoblot analysis.
Results:
Metabolic profiling by GC/MS analysis showed clear separation between the ischemia and control group (Figure A, B). The decrease of fructose 6-phosphate and ribulose 5-phosphate suggested enhancement of the pentose phosphate pathway (PPP) during cerebral ischemia. Transcriptional profiling by microarray hybridization indicated that Toll-like receptor and mitogen-activated protein kinase (MAPK) signaling pathway were upregulated during cerebral ischemia. In relation to PPP, upregulation of heat shock protein 27 (HSP27) was observed in the MAPK signaling pathway and was confirmed through RT-PCR. Immunoblotting showed a slight increase in HSP27 protein expression and a marked increase in HSP27 phosphorylation (FigureC). Corresponding upregulation of glucose 6-phosphate dehydrogenase (G6PD) activity and an increase in the NADPH/NAD+ ratio were also observed (Figure D, E).
Conclusions:
G6PD activation via ischemia-induced HSP27 phosphorylation may be part of an endogenous antioxidant neuroprotection mechanism during the earliest stages of ischemia.
Collapse
Affiliation(s)
- Yusuke Yamamoto
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | - Kohkichi Hosoda
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | | | - Yasuhiro Irino
- Div of Evidenced-based laboratory medicine, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | - Masakazu Shinohara
- The Integrated Cntr for Mass Spectrometry, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | - Jun Tanaka
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | - Tomoaki Nakai
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | - Naoko Sato
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| | - Eiji Kohmura
- Neurosurgery, Kobe Univ Graduate Sch of Medicine, Kobe, Japan
| |
Collapse
|
44
|
Nagano Y, Otake H, Harada A, Murakami K, Kiriyama M, Irino Y, Toba T, Takahashi H, Terashita D, Kuroda K, Uzu K, Tahara N, Shinkura Y, Nagasawa Y, Tsukiyama Y, Yanaka K, Yamamoto H, Shinke T, Ishida T, Toh R, Hirata KI. TCT-329 Impaired HDL uptake capacity which measure HDL functionality may associate with target lesion revascularization through provoking neoatherosclerosis formation after stent implantation. J Am Coll Cardiol 2016. [DOI: 10.1016/j.jacc.2016.09.460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Harada A, Toh R, Murakami K, Kiriyama M, Yoshikawa K, Kubo T, Miwa K, Irino Y, Mori K, Tanaka N, Ishida T, Hirata K. A potential role of cholesterol uptake capacity, a new measure for high-density lipoprotein functionality, in coronary risk stratification. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
46
|
Mori K, Ishida T, Tsuda S, Oshita T, Shinohara M, Hara T, Irino Y, Toh R, Hirata KI. Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy. J Atheroscler Thromb 2016; 24:123-132. [PMID: 27487947 PMCID: PMC5305673 DOI: 10.5551/jat.32615] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Aim: Clinical trials suggest that residual risks remain for coronary artery disease (CAD) during low-density lipoprotein cholesterol (LDL-C) lowering therapy. We aimed to investigate the role of exogenous lipids in the prognosis of CAD after percutaneous coronary intervention (PCI). Methods: A total of 145 patients with CAD, who underwent elective PCI, and 82 non-CAD (control) patients were enrolled in this study. CAD patients underwent follow-up coronary angiography 6–9 months after PCI, and were classified into three groups: 1) patients who showed in-stent restenosis (ISR) in the original stented segment, 2) patients with other non-target coronary atherosclerotic lesions (de novo), and 3) patients with neither ISR nor a de novo lesion. Biochemical analyses were performed on fasting serum samples at the time of follow-up coronary angiography. Results: Despite the controlled serum LDL-C levels, CAD patients with statin showed elevated cholesterol absorption marker campesterol/total cholesterol (TC), synthesis marker lathosterol/TC, campesterol/lathosterol ratio, and apolipoprotein B48 (apoB48) concentration compared with non-CAD patients. The high campesterol/TC, campesterol/lathosterol ratio, and apoB48 concentration were associated with de novo lesion progression after PCI. In stepwise multivariate logistic regression analysis, campesterol/TC and apoB48 concentrations were independent risk factors for de novo lesion progression in statin-treated CAD patients after PCI. Conclusion: The increase of cholesterol absorption marker and apoB48 concentration may lead to the progression of de novo lesions, and these markers may represent a residual risk during statin treatment after PCI.
Collapse
Affiliation(s)
- Kenta Mori
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Nagao M, Toh R, Irino Y, Mori T, Nakajima H, Hara T, Honjo T, Satomi-Kobayashi S, Shinke T, Tanaka H, Ishida T, Hirata KI. β-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes. Biochem Biophys Res Commun 2016; 475:322-8. [PMID: 27216458 DOI: 10.1016/j.bbrc.2016.05.097] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 05/19/2016] [Indexed: 12/31/2022]
Abstract
Recent studies have shown that the ketone body β-hydroxybutyrate (βOHB) acts not only as a carrier of energy but also as a signaling molecule that has a role in diverse cellular functions. Circulating levels of ketone bodies have been previously reported to be increased in patients with congestive heart failure (HF). In this study, we investigated regulatory mechanism and pathophysiological role of βOHB in HF. First, we revealed that βOHB level was elevated in failing hearts, but not in blood, using pressure-overloaded mice. We also measured cellular βOHB levels in both cardiomyocytes and non-cardiomyocytes stimulated with or without H2O2 and revealed that increased myocardial βOHB was derived from cardiomyocytes but not non-cardiomyocytes under pathological states. Next, we sought to elucidate the mechanisms of myocardial βOHB elevation and its implication under pathological states. The gene and protein expression levels of CoA transferase (SCOT), a key enzyme involved in ketone body oxidation, was decreased in failing hearts. In cardiomyocytes, H2O2 stimulation caused βOHB accumulation concomitantly with SCOT downregulation, implying that the accumulation of myocardial βOHB occurs because of the decline in its utilization. Finally, we checked the effects of βOHB on cardiomyocytes under oxidative stress. We found that βOHB induced FOXO3a, an oxidative stress resistance gene, and its target enzyme, SOD2 and catalase. Consequently, βOHB attenuated reactive oxygen species production and alleviated apoptosis induced by oxidative stress. It has been reported that hyperadrenergic state in HF boost lipolysis and result in elevation of circulating free fatty acids, which can lead hepatic ketogenesis for energy metabolism alteration. The present findings suggest that the accumulation of βOHB also occurs as a compensatory response against oxidative stress in failing hearts.
Collapse
Affiliation(s)
- Manabu Nagao
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Ryuji Toh
- Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Japan.
| | - Yasuhiro Irino
- Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Japan
| | - Takeshige Mori
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Hideto Nakajima
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Tetsuya Hara
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Tomoyuki Honjo
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Seimi Satomi-Kobayashi
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Toshiro Shinke
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Hidekazu Tanaka
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Tatsuro Ishida
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan
| | - Ken-Ichi Hirata
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University, Graduate School of Medicine, Japan; Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Japan
| |
Collapse
|
48
|
Nagashima H, Tanaka K, Sasayama T, Irino Y, Sato N, Takeuchi Y, Kyotani K, Mukasa A, Mizukawa K, Sakata J, Yamamoto Y, Hosoda K, Itoh T, Sasaki R, Kohmura E. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Neuro Oncol 2016; 18:1559-1568. [PMID: 27154922 DOI: 10.1093/neuonc/now090] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2016] [Accepted: 03/30/2016] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Mutations in the isocitrate dehydrogenase 1 (IDH1) gene that are frequently observed in low-grade glioma are strongly associated with the accumulation of 2-hydroxyglutarate (2HG), which is a valuable diagnostic and prognostic biomarker of IDH1 mutant glioma. However, conventional MR spectroscopy (MRS)-based noninvasive detection of 2HG is challenging. In this study, we aimed to determine the additional value of other metabolites in predicting IDH1 mutations with conventional MRS. METHODS Forty-seven patients with glioma underwent conventional single voxel short echo time MRS prior to surgery. A stereotactic navigation-guided operation was performed to resect tumor tissues in the center of the MRS voxel. MRS-based measurements of metabolites were validated with gas chromatography-mass spectrometry. We also conducted integrated analyses of glioma cell lines and clinical samples to examine the other metabolite levels and molecular findings in IDH1 mutant gliomas. RESULTS A metabolomic analysis demonstrated higher levels of 2HG in IDH1 mutant glioma cells and surgical tissues. Interestingly, glutamate levels were significantly decreased in IDH1 mutant gliomas. Through an analysis of metabolic enzyme genes in glutamine pathways, it was shown that the expressions of branched-chain amino acid transaminase 1 were reduced and glutamate dehydrogenase levels were elevated in IDH1 mutant gliomas. Conventional MRS detection of glutamate and 2HG resulted in a high diagnostic accuracy (sensitivity 72%, specificity 96%) for IDH1 mutant glioma. CONCLUSIONS IDH1 mutations alter glutamate metabolism. Combining glutamate levels optimizes the 2HG-based monitoring of IDH1 mutations via MRS and represents a reliable clinical application for diagnosing IDH1 mutant gliomas.
Collapse
Affiliation(s)
- Hiroaki Nagashima
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Kazuhiro Tanaka
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Takashi Sasayama
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Yasuhiro Irino
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Naoko Sato
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Yukiko Takeuchi
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Katsusuke Kyotani
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Akitake Mukasa
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Katsu Mizukawa
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Junichi Sakata
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Yusuke Yamamoto
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Kohkichi Hosoda
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Tomoo Itoh
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Ryohei Sasaki
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| | - Eiji Kohmura
- Department of Neurosurgery, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (H.N., K.T., T.S., N.S., K.M., J.S., Y.Y., K.H., E.K.); Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (Y.I., Y.T.); Center for Radiology and Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (K.K.); Department of Diagnostic Pathology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (T.I.); Division of Radiation Oncology, Kobe University Graduate School of Medicine and Kobe University Hospital, Kobe, Japan (R.S.); Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan (A.M.)
| |
Collapse
|
49
|
Hamamura K, Matsunaga N, Ikeda E, Kondo H, Ikeyama H, Tokushige K, Itcho K, Furuichi Y, Yoshida Y, Matsuda M, Yasuda K, Doi A, Yokota Y, Amamoto T, Aramaki H, Irino Y, Koyanagi S, Ohdo S. Alterations of Hepatic Metabolism in Chronic Kidney Disease via D-box-binding Protein Aggravate the Renal Dysfunction. J Biol Chem 2016; 291:4913-27. [PMID: 26728457 DOI: 10.1074/jbc.m115.696930] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Indexed: 11/06/2022] Open
Abstract
Chronic kidney disease (CKD) is associated with an increase in serum retinol; however, the underlying mechanisms of this disorder are poorly characterized. Here, we found that the alteration of hepatic metabolism induced the accumulation of serum retinol in 5/6 nephrectomy (5/6Nx) mice. The liver is the major organ responsible for retinol metabolism; accordingly, microarray analysis revealed that the hepatic expression of most CYP genes was changed in 5/6Nx mice. In addition, D-box-binding protein (DBP), which controls the expression of several CYP genes, was significantly decreased in these mice. Cyp3a11 and Cyp26a1, encoding key proteins in retinol metabolism, showed the greatest decrease in expression in 5/6Nx mice, a process mediated by the decreased expression of DBP. Furthermore, an increase of plasma transforming growth factor-β1 (TGF-β1) in 5/6Nx mice led to the decreased expression of the Dbp gene. Consistent with these findings, the alterations of retinol metabolism and renal dysfunction in 5/6Nx mice were ameliorated by administration of an anti-TGF-β1 antibody. We also show that the accumulation of serum retinol induced renal apoptosis in 5/6Nx mice fed a normal diet, whereas renal dysfunction was reduced in mice fed a retinol-free diet. These findings indicate that constitutive Dbp expression plays an important role in mediating hepatic dysfunction under CKD. Thus, the aggravation of renal dysfunction in patients with CKD might be prevented by a recovery of hepatic function, potentially through therapies targeting DBP and retinol.
Collapse
Affiliation(s)
- Kengo Hamamura
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan, the Drug Innovation Research Center, Daiichi University of Pharmacy, Minami-ku, Fukuoka 815-8511, Japan
| | - Naoya Matsunaga
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Eriko Ikeda
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan, the Drug Innovation Research Center, Daiichi University of Pharmacy, Minami-ku, Fukuoka 815-8511, Japan
| | - Hideaki Kondo
- the Center for Sleep Medicine, Saiseikai Nagasaki Hospital, Katafuchi, Nagasaki 850-0003, Japan
| | - Hisako Ikeyama
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Kazutaka Tokushige
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Kazufumi Itcho
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Yoko Furuichi
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Yuya Yoshida
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Masaki Matsuda
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Kaori Yasuda
- Cell-Innovator Inc., EC Building, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Atsushi Doi
- Cell-Innovator Inc., EC Building, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Yoshifumi Yokota
- the Department of Molecular Genetics, School of Medicine, Fukui University, Matsuoka, Fukui 910-1193, Japan
| | - Toshiaki Amamoto
- Neues Corporation, Tenyamachi-cho, Hakata-ku, Fukuoka 812-0025, Japan, and
| | - Hironori Aramaki
- the Drug Innovation Research Center, Daiichi University of Pharmacy, Minami-ku, Fukuoka 815-8511, Japan, the Department of Molecular Biology, Daiichi University of Pharmacy, Minami-ku, Fukuoka 815-8511, Japan
| | - Yasuhiro Irino
- the Integrated Center for Mass Spectrometry, Division of Membrane Biology, and Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Hyogo 650-0017, Japan
| | - Satoru Koyanagi
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan
| | - Shigehiro Ohdo
- From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan,
| |
Collapse
|
50
|
Tanaka K, Sasayama T, Irino Y, Nagashima H, Satoh N, Mischel P, Kohmura E. CBM-17INCREASING EXPRESSION OF GLUTAMINASE C (GAC) mRNA IN MALIGNANT GLIOMAS. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov211.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|